The QualityStocks Daily Wednesday, February 22nd, 2023

Today's Top 3 Investment Newsletters

QualityStocks(FAGI) $0.0240 +220.00%

The Stock Dork(LLAP) $2.9300 +71.35%

Schaeffer's(CVRX) $9.4700 +33.76%

The QualityStocks Daily Stock List

Full Alliance Group, Inc. (FAGI)

QualityStocks, ProTrader, Penny Stock Titans, Penny Picks, Damn Good Penny Picks and BullFreak reported earlier on Full Alliance Group, Inc. (FAGI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Full Alliance Group, Inc. is a multi-faceted holding company listed on the OTC Markets. It has various interests in technology, healthcare, and nutraceuticals. Nutra Yu, Inc. is a wholly owned subsidiary of Full Alliance Group. EBO2, Inc., is also a wholly owned subsidiary of the Company. Full Alliance Group has its corporate headquarters in Palm Desert, California.

The Company’s Nutra Yu subsidiary develops, markets, and distributes a proprietary line of nutraceutical products. The EBO2 subsidiary is the provider of ''EBO2'', a modern high volume blood gas exchange unit for the treatment of 5-7 liters of blood with medical ozone. The unit allows extracorporeal blood and oxygenation and ozone exposure and blood filtration through the filter in an innovative way by using the integrated diffusing membranes within the filter fibers to trap lipids and proteins that are in excess in the venous blood supply.

The EBO2 unit is considered the world's most advanced medical ozone therapy performed today. The EBO2 procedure is a minimally invasive intravenous therapy alike to hemodialysis developed as a treatment for numerous cardiological problems, allowing the patient to avoid life threatening, highly risky, painful, costly and complicated surgeries and long recovery periods.

Full Alliance Group’s mission is to provide technologically advanced, natural, nutritional products of unrivaled formulation, and also to educate consumers and healthcare practitioners in preventative healthcare and in bio-energetic systems for integrating overall wellness. The Company’s industries include Health & Wellness, Orthomolecular Medicine, Cardiovascular Health, Traditional Chinese Medicine (TCM), Nutraceuticals, and Quantum Energetic Medicine.

Full Alliance Group, Inc. (FAGI), closed Wednesday's trading session at $0.024, up 220%, on 13,611,302 volume. The average volume for the last 3 months is 292,189 and the stock's 52-week low/high is $0.0032/$0.0257.

Windtree Therapeutics (WINT)

QualityStocks, TraderPower, MarketBeat, StockMarketWatch, The Stock Dork, StreetInsider, MarketClub Analysis, InvestorsUnderground and InvestorPlace reported earlier on Windtree Therapeutics (WINT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Windtree Therapeutics Inc. (NASDAQ: WINT) is a medical device and clinical-stage biotechnology firm that is engaged in developing therapies for treating cardiovascular and acute pulmonary ailments.

The firm has its headquarters in Warrington, Pennsylvania and was founded in 1992, on November 6th by James S. Kuo and Evan Myrianthopoulos. Prior to its name change in April 2016, the firm was known as Discovery Laboratories Inc. The firm operates in the healthcare sector, under the biotech and pharma sub-industry and serves consumers in the U.S.

The enterprise is party to a collaboration agreement with the University of Milan-Bicocca, which entails discovering and developing new SERCA2a compounds for treating acute and chronic human heart failure. The enterprise is a subsidiary of Lee’s Pharmaceutical Holdings Ltd.

Windtree Therapeutics’ product pipeline is made up of a formulation developed for treating genetically associated hypertension which is known as Rostafuroxin and is currently undergoing phase 2 clinical trials; a lyophilized surfactant indicated for treating lung injuries caused by the coronavirus infection; an aerosolized surfactant indicated for the treatment of respiratory distress syndrome in premature infants dubbed Aerosurf, which is currently undergoing phase 2 clinical trials; and a drug formulation developed for treating early cardiogenic shock and acute decompensated heart failure dubbed Istaroxime, which is in phase 2a and 2b clinical trials.

The firm recently reported their financial results for the 2021 first quarter, which show that it expanded the participating cites and countries for its istaroxime clinical study and extended their collaboration with the University of Milan-Bicocca. The firm’s CEO noted that they were also focused on developing the business and would continue to advance their current and planned activities, which is bound to bring in more investors into the firm.

Windtree Therapeutics (WINT), closed Wednesday's trading session at $0.25, up 47.0588%, on 162,907,626 volume. The average volume for the last 3 months is 147,761 and the stock's 52-week low/high is $0.14/$1.43.

Bonso Electronics International (BNSO)

Wall Street Resources, QualityStocks, StockMarketWatch, MarketClub Analysis, Daily Stock Motion, Penny Pick Insider, Penny Stocks VIP, TradersPro, WINNINGOTC, OTCtipReporter, SMS Penny Picks, PennyStocks24, Wall Street Beauties, FatCat Stocks, Michael Stone, eliteotc.com, Growing Stocks Reports, Chatter Box Stocks, Promotion Stock Secrets, Research Driven Investor, TopPennyStockMovers, Wall Street Greek, Wall Street Mover and PennyStockScholar reported earlier on Bonso Electronics International (BNSO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bonso Electronics International Inc. (NASDAQ: BNSO) is focused on designing, developing, producing and selling electronic wireless and sensor-based products.

The firm has its headquarters in Tsim Sha Tsui, Hong Kong and was incorporated in 1980 by Hung Gun So. Prior to its name change in September 1988, the firm was known as Golden Virtue Ltd. It serves consumers around the globe, with a focus on the People’s Republic of China, Germany, Europe and the United States.

The company operates through the Rental and Management, Pet Electronics Products, Scales and Others segments. The rental and management segment provides leasing of machinery and factories to 3rd parties while the Pet products segment is involved in the development and production of pet-related electronic products for use in different consumer applications. On the other hand, the others segment covers mold and tooling charges for scales, pet electronics and telecommunications products. In addition to being involved in the sale of scrap materials, the scales segment is engaged in the provision of sensor-based scales products, which include postal, laboratory, jewelry, office, kitchen, bathroom and industrial scales for industrial, commercial and consumer applications.

The enterprise serves original design manufacturers, original brand manufacturers and original equipment manufacturers internationally. It also sells its pet electronic products through various online platforms.

The company recently reported its latest financial results which show increases in its net revenues. It is focused on investing and developing new models of electronic scales and pet electronic products in order to remain competitive. This move will not only bring in more revenues into the company but also extend its consumer reach.

Bonso Electronics International (BNSO), closed Wednesday's trading session at $4.85, up 25.974%, on 318,978 volume. The average volume for the last 3 months is 3.434M and the stock's 52-week low/high is $2.26/$12.09.

American International Holdings Corp. (AMIH)

QualityStocks, StockOnion, Profitable Trader Authority, PennyStockScholar, PennyStockProphet, Penny Pick Finders, OTCtipReporter and Buzz Stocks reported earlier on American International Holdings Corp. (AMIH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

American International Holdings Corp. is a diversified holding company listed on the OTC Markets. Its commitment is to acquiring, managing, and operating health, wellness, beauty, and lifestyle companies, businesses and/or brands located in the U.S. and internationally. The Company looks for opportunities to acquire and grow businesses that have strong brand values and that can produce long-term sustainable free cash flow and attractive returns to maximize value for American International and its stakeholders. Incorporated in 1986, American International Holdings has its corporate headquarters in Addison, Texas.

American International owns and operates a medical spa under the Novopelle brand name in McKinney, Texas. It also has its wholly-owned subsidiary, Capitol City Solutions USA, Inc. (CCS). CCS was formed to act as a general contracting and construction company centered on the remodeling, general construction, and interior finish of American International’s Novopelle branded med spa locations, as well as to market to other commercial real estate projects within the United States.

American International Holdings’ wholly-owned subsidiary, Novopelle Waterway, Inc. officially opened the doors to its Novopelle Med Spa located at the award-winning Woodlands Waterway in The Woodlands, Texas, on Tuesday, February 25, 2020. This is the second Novopelle Med Spa location to be established and operated by the Company.

American International Holdings’ dedication is also to operating and managing an online platform providing customers with access to life and career coaches via LifeGuru, Inc. (www.LifeGuru.me, which is now in development). Moreover, its dedication is to operating and managing an online telemedicine platform connecting customers to Board certified physicians and licensed mental and behavioral health counselors via ZipDoctor, Inc. (www.ZipDoctor.co).

American International Holdings previously announced that it has retained the services of Captify Consulting to lead, support, as well as champion the ZipDoctor’s digital marketing and social media advertising efforts as it relates to its recently launched subscription based online telemedicine platform, located at www.ZipDoctor.co. ZipDoctor’s online telemedicine platform is available to customers throughout the U.S. It offers bilingual coverage (English and Spanish), with virtual visits taking place either through the phone or via a secured video chat platform. Captify specializes in helping B2C (Business 2 Consumer) companies, eCommerce Brands, and entrepreneurs scale and boost their revenue with highly-targeted, consistently-converting digital advertisement campaigns.

American International Holdings Corp. (AMIH), closed Wednesday's trading session at $0.01355, up 34.1584%, on 20,712,690 volume. The average volume for the last 3 months is 21,448 and the stock's 52-week low/high is $0.0029/$1.49.

Tempo Automation (TMPO)

MarketBeat reported earlier on Tempo Automation (TMPO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Tempo Automation Holdings Inc. (NASDAQ: TMPO) is a holding firm that operates as a software-accelerated manufacturer of electronic products.

The firm has its headquarters in San Francisco, California and was incorporated in 2013. Prior to its name change, the firm was known as ACE Convergence Acquisition Corp. It operates as part of the electronic components industry, under the technology sector. The firm serves consumers across the globe.

The company is focused on transforming the way top firms innovate and bring new products to market. Its unique automated manufacturing platform optimizes the complex process of printed circuit board manufacturing to deliver unmatched quality, speed and agility. The platform's all-digital process automation, data-driven intelligence, and connected smart factory create a distinctive competitive advantage for customers to deliver tomorrow's products today.

The enterprise specializes in prototyping and low-volume production of printed circuit board assemblies (PCBAs). Its PCBA services include turnkey PCB assembly and manufacturing, rapid PCBA prototyping, on-demand PCBA manufacturing and supply chain solutions. It also specializes in PCBA production with military-grade reliability for terrestrial, avionics, ground control, and payload applications. It serves a range of industries, including the automotive, aviation and defense, consumer electronics, design firms, energy, industrial technology, medical device, semiconductor and space industries.

The firm, which recently announced its latest financial results, added powerful new tools to its Accelerated Electronics Manufacturing Platform. This will help to better meet consumer needs while also guarding against supply chain disruptions in the electronics industry.

Tempo Automation (TMPO), closed Wednesday's trading session at $1.39, up 6.9231%, on 53,868 volume. The average volume for the last 3 months is 174,915 and the stock's 52-week low/high is $0.70/$15.15.

SigmaTron International (SGMA)

MarketClub Analysis, TradersPro, Broad Street, Zacks, Wall Street Resources, TopPennyStockMovers, MarketBeat, Marketbeat.com, StreetInsider, StocksEarning, SmarTrend Newsletters, AwesomeStocks, GorillaTrades, Investing Futures, Market FN, AnotherWinningTrade, QualityStocks, Stock Research Newsletter, StockMarketWatch, Street Insider, The Best Newsletters and PoliticsAndMyPortfolio reported earlier on SigmaTron International (SGMA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

SigmaTron International Inc. (NASDAQ: SGMA) (FRA: SG3) is an independent provider of electronic manufacturing services (EMS).

The firm has its headquarters in Elk Grove Village, Illinois and was incorporated in 1993, on November 16th. It operates as part of the electronic components industry, under the technology sector. The firm serves diverse end-user markets through a network of 7 manufacturing facilities located in Vietnam, Mexico, the United States and China.

The company’s One Source, Global Options approach to delivering EMS solutions adds flexibility to its clients’ outsourcing strategy. It also has an International Procurement Office in Taiwan.

The enterprise’s EMS services include printed circuit board assemblies and completely assembled (box-build) electronic products. It also provides automatic and manual assembly and testing of products; design services; material sourcing and procurement services; manufacturing and test engineering support services; warehousing and distribution services; and assistance in obtaining product approval from governmental and other regulatory bodies. In addition to this, it offers electronic and electromechanical manufacturing solutions. The enterprise primarily serves consumer electronics, industrial electronics, and medical/life sciences industries in Taiwan, the United States, China, Mexico and Vietnam. It markets its services through independent manufacturers' representative organizations.

The firm, whose latest financial results show increases in its revenues, recently appointed a new President of EMS Operations. The appointee has extensive experience in the industry, having been in the firm for decades. This will be of use as the firm continues to grow and create value for its shareholders.

SigmaTron International (SGMA), closed Wednesday's trading session at $3.9, off by 2.2556%, on 6,701 volume. The average volume for the last 3 months is 1.093M and the stock's 52-week low/high is $3.60/$10.28.

Molekule Group (MKUL)

We reported earlier on Molekule Group (MKUL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Molekule Group Inc. (NASDAQ: MKUL) is an interior space air purification technology firm that is engaged in the provision of air purification solutions for hospitals and other healthcare facilities.

The firm has its headquarters in Palm Beach Gardens, Florida and was incorporated in 2011, on September 2nd by Mark Krosney, David Helfet and Amin J. Khoury. Prior to its name change in January 2023, the firm served consumers as AeroClean Technologies Inc. It operates as part of the pollution and treatment controls industry, under the industrials sector. The firm serves consumers around the globe.

The enterprise provides interior air sterilization and disinfection products for the eradication of harmful airborne pathogens, including COVID-19. Its photo electrochemical oxidation (PECO) technology destroys a range of pollutants, including mold, bacteria, viruses, and allergens. Its air purifiers include Air Pro and Air Mini+. Its filters include Air Mini & Mini+ PECO-HEPA Tri-Power Filter, Air Pro PECO-HEPA Tri-Power Filter, Air Mini / Air Mini+ PECO-Filter, Air Pro PECO-Filter, Air pre-filter 2-pack and Air PECO-Filter. It is also focused on the development of its Safe Air as a Service, indoor air quality (IAQ) monitoring and Internet-of-things (IoT) device control solution that helps to improve customer IAQ and measure sustainability across their enterprises.

The company, which is set to showcase its expertise on indoor air quality management in an upcoming conference, remains focused on driving greater adoption of its growing range of products and services. This will extend its consumer reach while also bringing in additional revenues into the company.

Molekule Group (MKUL), closed Wednesday's trading session at $2.82, off by 0.704225%, on 60,156 volume. The average volume for the last 3 months is 407 and the stock's 52-week low/high is $1.76/$23.70.

Energy Services of America (ESOA)

QualityStocks, MarketBeat, StocksEarning, StockEarnings, Real Pennies, MarketClub Analysis and Marketbeat.com reported earlier on Energy Services of America (ESOA), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Energy Services of America Corp (NASDAQ: ESOA) is a contractor and service firm that is engaged in the provision of contracting services for utilities and energy-related firms.

The firm has its headquarters in Huntington, West Virginia and was incorporated in 2006, on March 31st. It operates as part of the engineering and construction industry, under the industrials sector. The firm serves consumers in the United States, with a focus on those in West Virginia, Ohio, Kentucky, Pennsylvania and Virginia. It operates through West Virginia Pipeline Inc. and C.J. Hughes Construction Company Inc.

The enterprise constructs, replaces, and repairs interstate and intrastate natural gas pipelines and storage facilities for utility companies and private natural gas companies; and provides services relating to pipeline, storage facilities, and plant works. It also offers a range of electrical and mechanical installation, and repair services, including substation and switchyard, site preparation, equipment setting, pipe fabrication and installation, packaged buildings, transformers, and other ancillary works for the gas, petroleum power, chemical, water and sewer, and automotive industries. In addition, the company provides liquid pipeline and pump station construction, production facility construction, water and sewer pipeline installation, and various maintenance and repair services, as well as other services related to pipeline construction.

The company recently announced its latest financial results, with it CEO noting that they remained focused on advancing its ongoing projects, which included a new school construction project and an EV battery project. This will open it up to new growth and investment opportunities, which will help create shareholder value.

Energy Services of America (ESOA), closed Wednesday's trading session at $2.52, off by 0.395257%, on 12,057 volume. The average volume for the last 3 months is 1.459M and the stock's 52-week low/high is $1.77/$4.678.

SHF Holdings (SHFS)

QualityStocks, MarketBeat and FreeRealTime reported earlier on SHF Holdings (SHFS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Safe Harbor Financial (SHF) Holdings Inc. (NASDAQ: SHFS) is a service provider engaged in the provision of access to banking, lending and other financial services to financial institutions serving cannabis, hemp, cannabidiol (CBD), and ancillary operators.

The firm has its headquarters in Arvada, Colorado and was incorporated in 2015. It operates as part of the banks-regional industry, under the financial services sector. The firm serves consumers in the United States, with a focus on those in the state of Colorado.

The company is focused on creating a safer and thriving community. Its services continually grow and evolve to meet client needs today and navigate into the future. As cannabis banking specialists, they has have the tools and systems needed to be more successful and become a cannabis industry leader. It operates through its subsidiaries. The company’s parent organization is Partner Colorado Credit Union.

The enterprise provides loans to cannabis businesses and cannabis business owners for purchasing a commercial property, refinancing an existing commercial real estate loan, and cashing-out on an existing commercial property. It offers its services through Cannabis Banking Solutions Platform. They include business loans, business checking and savings accounts, payment solutions, cash management accounts, electronic tax filing, remote deposit, mobile banking, debit cards, cash management accounts, automated clearing house (ACH) wire services, cash pick-up and delivery services, investment options, and sweep options.

The company, which recently appointed a new Board member, remains focused on expanding its leadership in the legal fintech space. This will extend its consumer reach while also bringing in additional revenues and investments into the company.

SHF Holdings (SHFS), closed Wednesday's trading session at $0.781, off by 1.6125%, on 33,781 volume. The average volume for the last 3 months is 23.462M and the stock's 52-week low/high is $0.6721/$30.47.

DoubleDown Interactive Co. Ltd. (DDI)

InvestorBrandNetwork, QualityStocks, MarketBeat, Zacks, The Stock Dork and InvestorPlace reported earlier on DoubleDown Interactive Co. Ltd. (DDI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

DoubleDown Interactive (NASDAQ: DDI), a leading gaming company delivering unique player experiences across a variety of genres, announced that it has changed is independent registered public accounting firm. DDI will be working with Samil PricewaterhouseCoopers (“PwC”) firm for the fiscal year, ending Dec. 31, 2023; Samil PwC is replacing Ernst & Young LLP (“EY”). According to the announcement, the company made the decision “in reference to the change in external auditor of DoubleU Games Co. Ltd., a Korean company and the controlling shareholder of the company, which was mandated by the Act on External Audit of Stock Companies of Korea and the related regulations thereunder. Pursuant to the act, the Securities and Futures Commission of the Financial Services Commission of Korea has appointed PwC as the external auditor of DUG for the fiscal year ending Dec. 31, 2023. As such, the company has determined that it would be in the best interest of the company to engage the same auditor as its independent registered public accounting firm.”

To view the full press release, visit https://ibn.fm/eHQZP

About DoubleDown Interactive Co. Ltd.

DoubleDown Interactive is a leading developer and publisher of digital games on mobile and web-based platforms. The company is the creator of multiformat interactive entertainment experiences for casual players, bringing authentic Vegas entertainment to players around the world through an online social casino experience. DDI’s flagship title, DoubleDown Casino, has been a fan-favorite game on leading social and mobile platforms for years, entertaining millions of players worldwide with a lineup of classic and modern games. For more information about this company, please visit www.DoubleDownInteractive.com.

DoubleDown Interactive Co. Ltd. (DDI), closed Wednesday's trading session at $9.5, off by 1.2474%, on 11,854 volume. The average volume for the last 3 months is 889,565 and the stock's 52-week low/high is $8.00/$13.385.

Seelos Therapeutics Inc. (SEEL)

QualityStocks, MarketBeat, StockMarketWatch, MarketClub Analysis, TradersPro, Schaeffer's, BUYINS.NET, Trades Of The Day and INO Market Report reported earlier on Seelos Therapeutics Inc. (SEEL), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Aging is the number one cause of suffering and death globally, as noted by Dr. Andrew Steele, who authored a book on longevity. Steele, who’s majored in physics, argues that people could live to 200 if we came up with pharmacological solutions to eliminate the cells that degrade tissue function.

One study carried out by scientists at Harvard Medical School found that epigenetics could drive aging in an organism. The research, which used mice models, demonstrated that a breakdown in epigenetic data caused the animals to age. The researchers also observed that reinstating the integrity of the epigenome reversed these signs of aging.

Professor David Sinclair of the Blavatnik Institute at the Harvard School of Medicine stated that this finding supported the theory that cells in mammals possessed a copy of epigenetic data that could be used to reboot aged cells into healthy, youthful states when accessed. Sinclair is also the codirector of the Paul F. Glenn Center for Biology of Aging Research. His company, Life Biosciences, is focused on the development of therapies to treat, prevent or reverse various aging-related illnesses, with the objective being to extend a human’s lifespan.

The company plans to include psychedelics in its studies, as the applications for these drugs in mental health treatments continue to grow. The company recently secured $158 million in funding for its research.

Last year, the Longevity Science Foundation committed $1 billion to institutions, research and projects to advance healthy human longevity. The nonprofit organization is focused on funding psychedelics companies that will look into the use of new or existing psychedelics in delaying, managing or reversing age-associated brain and mental illnesses.

Thus far, studies have proven that psilocybin and ketamine can regrow neural connections, which will be useful in the development of therapies for aging-related neurodegenerative illnesses in the future. It is common knowledge that aging is linked to reductions in neuroplasticity, with researchers noting that age-related decline in neuroplasticity may significantly contribute to neuronal and synaptic loss in Alzheimer’s.

Researchers have already identified drugs that can extend lifespans in animals. One of these medications, rapamycin, has demonstrated characteristics to prevent aging in animal models. This is in addition to showing that the drug can delay Alzheimer’s onset and reduce cognitive decline. Metformin, a diabetes treatment, has also shown promise in this field of research. Sinclair expects that reversing aging in an individual could become a reality in the next two or three years.

Given that significant research resources are being devoted to psychedelic studies by the likes of companies such as Seelos Therapeutics Inc. (NASDAQ: SEEL), more information is likely to be revealed about other benefits and possible risks of different psychedelic compounds.

Seelos Therapeutics Inc. (SEEL), closed Wednesday's trading session at $0.72, off by 1.2617%, on 477,024 volume. The average volume for the last 3 months is 435,934 and the stock's 52-week low/high is $0.4803/$1.52.

Royal Gold Inc. (RGLD)

TopStockAnalysts, Streetwise Reports, StreetAuthority Daily, InvestorPlace, TradingAuthority Daily, The Street, MarketBeat, Daily Wealth, Top Pros' Top Picks, QualityStocks, StreetInsider, Daily Trade Alert, SmarTrend Newsletters, TheStockAdvisor, All about trends, Energy and Capital, Zacks, Money Morning, MarketClub Analysis, The Growth Stock Wire, TheStockAdvisors, Trades Of The Day, Dividend Opportunities, Marketbeat.com, Wyatt Investment Research, Barchart, Wealth Daily, Uncommon Wisdom, Lebed.biz, Investor Update, Daily Profit, Schaeffer's, Investment U, Money and Markets, National Inflation Association, Stockhouse, The Online Investor, Traders For Cash Flow, TradingMarkets, Trade of the Week, Forbes, Market Intelligence Center Alert, Outsider Club, Greenbackers, Weekly Wizards, Kiplinger Today, FNNO Newsletters, AllPennyStocks, Dynamic Wealth Report, GorillaTrades, Bourbon and Bayonets, BestChartNow, Wealth Insider Alert, ChartAdvisor, DividendStocks.com, Stocks That Move, Penny Stock Chaser, PowerRatings Stocks, Profits Run, Short Term Wealth, Stansberry Research, Hit and Run Candle Sticks, Market Authority, One Hot Stock, StocksEarning, Investopedia, The Best Newsletters, Investing Futures, Inside Investing Daily, INO.com Market Report and Market FN reported earlier on Royal Gold Inc. (RGLD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Last week, the price of gold dropped slightly as the Federal Reserve pushed on with its hawkish stance on rate hikes. Demand concerns also affected palladium negatively, with the metal dropping to its lowest figure since 2019. At the same time, U.S. gold futures rose 1% to reach $1,851.80 while spot gold remained unchanged at $1,852.94 an ounce.

Recently released consumer data also shows that America’s CPI increased by 6.4% in the 12 months through January. On a monthly basis, CPI rose by 0.5% in January.

The increase in gold last week came  week after the greenback dropped to a near two-week low. However, the dollar recovered shortly after, which made the precious metal more expensive for buyers overseas. Against the yen, the greenback was up by 0.5% at 130.24 yen. Against the euro, the dollar was 0.2% higher.

High Ridge Futures’ director of Metals Trading, David Meger, stated that there is still concern that the Federal Reserve could become more aggressive with its rate hikes in an effort to fight inflation in the country. This, Meger noted, would weigh on gold.

President of the Dallas Federal Reserve Lorie Logan and Tom Barkin, president of the Richmond Fed, both agreed that the Central Bank would need to concentrate on reducing inflation down to the 2% target.

Insured unemployment rate, weekly jobless claims and private sector payrolls are some of the high-frequency inflation indicators considered by the Fed.

Oil prices are said to be the primary driver of U.S. inflation, affecting more than 70% of the total inflation. Diesel’s retail price has been the sole most significant predictor of inflation in the country. Other inflation predictors have been the OECD GDP growth tracker and the Johnson Redbook index.

The Federal Reserve is expected to increase its policy rate at least two more times, going as high as 5 to 5.25%. Bullion is sensitive to increasing rates of interest in the United States, which in turn increases the opportunity cost of holding the asset. Palladium also slipped by more than 4% to reach $1,500.18 an ounce. This was shortly after touching $1,468.94 per ounce, its lowest price since August 2019.

In a note, analysts at Commerzbank stated that the growing use of platinum as a substitute for palladium and the increase in the demand for electric vehicles would reduce the demand for palladium for the production of new cars. Platinum dropped 2.3% to reach $931.61 while spot silver declined by 0.6% to hit $21.84.

One can bet that gold extractors such as Royal Gold Inc. (NASDAQ: RGLD) will be keeping a close eye on how the Fed’s actions affect the markets.

Royal Gold Inc. (RGLD), closed Wednesday's trading session at $119.37, off by 1.7045%, on 441,055 volume. The average volume for the last 3 months is 49 and the stock's 52-week low/high is $84.54/$147.70.

The QualityStocks Company Corner

Cybin Inc. (NEO: CYBN) (OTC: CYBN)

The QualityStocks Daily Newsletter would like to spotlight Cybin Inc. (NEO: CYBN) (NYSE American: CYBN).

Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin ” or the “ Company ”), abiopharmaceutical company focused on progressing Psychedelics toTherapeutics ® today announced a streamlining plan aimedat maximizing the Company’s operating efficiency and to allow theCompany to focus on critical clinical trials. Based on anticipatedcost savings from the streamlining exercise and the Company’songoing and previously announced US$35 million At-The-Market(“ATM”) equity program, management believes the Company will bebetter positioned for both near-term and long-term success. TheCompany anticipates these cost savings will result in a decrease inits historical annual cash burn rate by millions of dollars, whileCybin continues to push forward on all core clinical initiatives.Today, the Company has released approximately 15% of its workforcethat previously held roles that were not of a clinical priority orwere not directly involved with any of the Company’s clinical trialinitiatives. As a result of the headcount reductions, the Companyexpects to generate cost savings from reducing operating expenses.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is a Canada-based life sciences company focused on the pharmaceutical development of psychedelic products, as well as the functional mushroom market.

The early-stage company boasts an experienced management team featuring industry veterans from pharmaceutical and consumer product backgrounds who have run multiple clinical trials and collectively helped facilitate billions of dollars in product revenues. The team is dedicated to the development of products and protocols within the psychedelic, pharmaceutical and nutraceutical industries.

In particular, Cybin aims to further build upon and expand its intellectual property (IP) portfolio, which is structured around unique psilocybin delivery mechanisms that target a number of different therapeutic indications. In addition, the company has dedicated itself toward furthering its research and IP within the fields of synthetic compounds, extraction methods, the isolation of chemical compounds, new drug formulations and protocol regimes.

Serenity Life Sciences & Natures Journey Inc.

The company’s business model is centered around its two core subsidiaries, Serenity Life Sciences and Natures Journey Inc., which comprise Cybin’s two-pronged approach toward delivering fungi-derived psychedelic and medicinal products.

Serenity Life Sciences is focused on furthering research and development of psilocybin-based medications. Psilocybin is found in certain species of mushrooms and is a non-habit forming, naturally occurring psychedelic compound. Research into psilocybin has shown positive results for the treatment of depression, anxiety, PTSD, addiction, eating disorders, ADHD and other indications.

Natures Journey Inc. operates the Journey brand, which specializes in developing proprietary medicinal mushroom products that target and promote mental wellness, immune boosting detoxification and overall general health and wellbeing.

Partnership with the Toronto Centre for Psychedelic Science (TCPS)

Staying true to its axiom of being a research-first medicinal mushroom life sciences company, Cybin recently announced its entry into a strategic partnership with the Toronto Centre for Psychedelic Science (TCPS), with the goal of furthering its ongoing psilocybin research efforts and expanding Cybin’s psilocybin IP portfolio (http://nnw.fm/9EUkI).

“While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach,” Paul Glavine, CEO of Cybin, stated in a news release.

“We are excited to join forces with Cybin and to offer our expertise. A number of firms had approached TCPS, but Cybin demonstrated a superior commitment to high-quality research and integrity in product development. Our high standards for scientific rigor and transparency will find a fitting home within the culture Cybin is cultivating in Canada and abroad,” Thomas Anderson, co-founder of the Toronto Centre for Psychedelic Science, added.

Journey’s Product Monetization & Market Potential for Nutraceutical Supplements

Although Cybin is at the forefront of companies seeking to conduct clinical trials aimed at gaining regulatory approval for psilocybin and other psychedelic products, the company has also placed a great deal of emphasis on generating meaningful revenue from its very outset.

Cybin’s Journey brand has is launching a range of supplements comprised of popular fungi-derived ingredients such as Reishi, Lion’s Mane and Cordyceps. Purported to aid focus and concentration while promoting neurogenesis, Journey’s range of nutraceutical products provides Cybin with a crucial foothold within the non-psychedelic legal supplement market, which is valued at over $25 billion globally and growing at a 9% year-over-year rate.

Pharmaceutical Psychedelics

In addition to the company’s range of non-psychedelic supplements, Cybin has plans to carry out a clinical trial with a new delivery system for its psilocybin-based medications later this year. Ultimately, the company aims to enter into technology transfer agreements with global pharmaceutical companies after phase 1 & phase 2 clinical trials are complete in order to accelerate regulatory approvals in major indications in global markets with entire lifecycle product management.

With products such as psilocybin truffles already legal in nations such as the Netherlands, Jamaica and Bulgaria, Cybin has positioned itself to capitalize on an eventual legalization of psychedelic mushroom-derived products in the future. Working within a regulatory environment with strong similarities to that which dealt with cannabis prior to the industry’s eventual legalization by the Canadian government in 2018, Cybin is laying the groundwork for the moment pharmaceutical psychedelics gain acceptance in North America and abroad.

Amalgamation Agreement and Financing

Cybin recently announced its entry into an amalgamation agreement dated June 26, 2020, with Clarmin Explorations Inc. (TSX.V: CX) and 2762898 Ontario Inc., a wholly owned subsidiary of Clarmin (http://nnw.fm/w04LH). Completion of the transactions contemplated in the amalgamation agreement will result in the reverse takeover of Clarmin by Cybin.

In connection with the proposed transaction, Cybin plans to complete a “best-efforts” brokered private placement of subscription receipts of Cybin, with a syndicate of agents co-led by Stifel Nicolaus Canada Inc. (Stifel GMP) and Eight Capital, to raise a minimum of C$14 million ($10 million) and a maximum of C$21 million ($15 million), with a 15% agents’ option.

To date, Cybin has raised approximately C$10,400,000 through an initial financing round and its series A financing round.

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), closed Wednesday's trading session at $0.5099, up 7.3474%, on 2,239,413 volume. The average volume for the last 3 months is 501 and the stock's 52-week low/high is $0.2649/$1.14.

Recent News

India Globalization Capital Inc. (NYSE American: IGC)

The QualityStocks Daily Newsletter would like to spotlight India Globalization Capital Inc. (NYSE American: IGC).

The American Society of Addiction Medicine, a top addictiontreatment organization, is advocating for the legalization of all drugs that are currently illegal in the name of racial equity and public health. The organization,which has always sided with antidrug advocates and opposed even themildest cannabis reforms, has significantly changed its stance on drug-related policies in the past few years. While the organization has advocated fordecriminalizing marijuana since 2015, it is now urging thedecriminalization of all drugs, including the elimination ofcriminal penalties for paraphernalia, citing the stigma andinstitutionalized racism that are deeply embedded in the nation’sdrug policy. The group released three policy statements on Feb. 9, 2023, in which it advocated for the elimination ofharsh civil and criminal penalties for the possession of drugs anddrug accouterments for adult-use as part of a broader set ofinterlinked legal and public health reforms intended to enhanceseveral carefully chosen outcomes. In addition to legalizing drugs,ASAM argued that lawmakers take into account the possibility ofexpunging records of prior offenses of this nature so that citizensare not still ostracized for them. The organization citedPortugal’s decriminalization laws and claimed that the reform mayresult in health improvements based on the available data. ASAM’spush for ending cannabis criminalization is no surprise given thatfor-profit enterprises such as India Globalization Capital Inc. (NYSE American: IGC) are making plenty of headway in taking cannabis-based formulationsthrough the clinical-development process in a bid to obtainregulatory approval for those novel therapeutics, proving thatmarijuana does have medicinal potential.

India Globalization Capital Inc. (NYSE American: IGC), through subsidiary IGC Pharma, develops, patents, and markets advanced THC-based drug formulations for the treatment of symptoms related to various diseases including but not limited to Alzheimer’s disease, Tourette syndrome, chronic pain, and pet seizures.

IGC’s leading drug candidate, IGC-AD1, has completed Phase 1 of a safety and tolerability trial and entered Phase 2 trials for treating agitation in patients with Alzheimer’s dementia, the first study in humans of a natural tetrahydrocannabinol (THC) compound plus another molecule (www.clinicaltrials.gov). As of September 2022, the IGC trial is the only ongoing Phase 2 trial of a natural THC-based formulation on Alzheimer’s patients.

The company’s other drug candidate, TGR-63, is an enzyme inhibitor that has shown in preclinical trials the potential to reduce neurotoxicity in Alzheimer’s cell lines. Both drug candidates have shown their ability to ameliorate beta amyloid plaques in Alzheimer’s cell lines and improve memory in Alzheimer’s mouse models. Beta amyloid plaques are a key hallmark of Alzheimer’s and an important target of Alzheimer’s pharmaceutical drug development.

Neuro Psychiatric Symptoms (NPS) are not only debilitating for Alzheimer’s patients; they also place an immense emotional burden on their caregivers. Beyond reducing symptoms, IGC-AD1’s active molecules and TGR-63 have also shown promise in preclinical trials to reduce important hallmarks of Alzheimer’s including plaques and tangles, as well as improving the treatment of memory loss.

Over the past eight years, the IGC team has amassed a deep knowledge of cannabinoid science, including extraction, isolation, purification, and development. The company’s strategy is to leverage its unique end-to-end capabilities, platform, and expertise to develop a class-leading program and bring it to market quickly and cost efficiently to treat neurodegenerative diseases such as Alzheimer’s.

The company also has a family of cannabidiol (CBD)-based consumer products (www.Holief.com) such as pain relief creams, pain relief gels, purpose gummies, tinctures, and capsules targeting women’s wellness, with a particular focus on premenstrual syndrome (PMS) and dysmenorrhea (period cramps). In addition, the company targets individuals that need sleep-aids with its specially formulated low melatonin cannabinoid gummies.

IGC has also introduced a low-calorie CBD- and caffeine-infused energy beverage brand (www.SundaySeltzer.com) that is currently available for purchase. The company’s brands are founded on the belief that effective natural solutions should be affordable and accessible to everyone. As the demand for natural products targeting women’s wellness and energy drinks continue to grow, these products are seeing strong traction in the market.

The company operates three facilities – a large GMP (Good Manufacturing Production Standards) certified facility that includes extraction, distillation, and manufacturing, in Washington State; a GMP-211 (pharmaceutical) grade facility in Maryland; and a facility licensed for controlled substances including cannabis in Bogota, Colombia, with complete access to legal licensed cannabis where the company conducts its testing.

In addition, the company’s development under Magistral Formulations is approved by INVIMA (Colombia National Food and Drug Surveillance Institute) to treat neurological disorders, non-oncological chronic pain, and mental disorders.

IGC’s intellectual property (IP) portfolio comprises of eight patents that it controls and seven patent applications. The portfolio includes #11,446,276, a patent for extreme low dose THC treatment of Alzheimer’s that was granted in September 2022.

The company is headquartered in Potomac, Maryland.

IGC-AD1

IGC-AD1 is the company’s leading drug candidate for the treatment and relief of Alzheimer’s symptoms. A significant amount of research on Alzheimer’s cell lines has shown that the active agents in IGC-AD1 reduce plaques and neurofibrillary tangles that are the hallmarks of Alzheimer’s. Further, micro-dosing of THC, as shown in cell lines, could increase the functioning of mitochondria and potentially promote the growth of new neural pathways (neurogenesis). The research shows that micro-dosing of THC affects the brain radically differently from the normal higher dosing of THC.

While there is a significant body of research showing that THC is neuro-toxic at normal levels of dosing, micro-dosing of THC has been shown to be non-toxic to neurons. With the results of these preclinical studies, the company developed an oral formulation, IGC-AD1. The company recently completed a safety and tolerability Phase 1 trial on Alzheimer’s patients and has initiated a Phase 2, multi-site, double-blind, randomized, placebo-controlled trial of the safety and efficacy of IGC-AD1 on agitation in participants with dementia due to Alzheimer’s disease at sites in the U.S. and Canada. IGC expects the Phase 2 trial to take between 9 and 12 months to complete, barring unknown factors such as, for example, a resurgence of COVID and the enforcement of lockdowns and travel restrictions.

With further successful trials and FDA approvals, IGC hopes to bring a drug based on natural THC as an effective treatment for agitation in Alzheimer’s to market.

TGR-63

The company’s other molecule, TGR-63, has been shown to reduce the neurotoxicity that impacts memory loss in preclinical trials with mice. On a dose dependent manner, transgenic Alzheimer’s mice treated with TGR-63 showed improvement in memory relative to control.

Both drug candidates, IGC-AD1 and TGR-63, have shown their ability to reduce the brain plaques associated with memory loss in Alzheimer’s in mice.

With further successful trials and FDA approvals, IGC hopes to bring TGR-63 as a treatment for Alzheimer’s disease to market.

Market Opportunity

Alzheimer’s disease impacts over 55 million people worldwide and about 5.5 million individuals in the U.S. Over 70% of these patients face debilitating symptoms, including anxiety, depression, and agitation (Mendez, 2021). Agitation in dementia patients can include excessive physical movement and verbal activity, restlessness, pacing, belligerence, aggression, screaming, crying, and wandering.

In 2020, the estimated healthcare costs for Alzheimer’s disease in the U.S. were $305 billion. Medicare and Medicaid covered about 70% of those costs, leaving considerable burden on patients and families. At the current rate of growth of Alzheimer’s and other dementia diagnoses, those costs are estimated to reach over $1 trillion by 2050.

Currently, there are no FDA-approved medications to alleviate the symptoms of dementia due to Alzheimer’s disease, providing a tremendous opportunity for formulations that can have an impact on quality of life and disease progression.

Management Team

Richard Prins has been chairman at IGC since 2012 and served as an independent director since 2007. From March 1996 to 2008, he was the Director of Investment Banking at Ferris, Baker Watts, Incorporated. Prins served in a consulting role to RBC until January 2009. He currently volunteers full time with a non-profit organization, Advancing Native Missions, and is a private investor. Since February 2003, he has been on the board of Amphastar Pharmaceuticals Inc. He holds a bachelor’s degree from Colgate University and an MBA from Oral Roberts University.

Ram Mukunda is CEO and President of IGC. He has been the chief inventor and architect of most of the company’s patent filings and is responsible for the company’s strategic positioning. Prior to IGC, he was founder and CEO of Startec Global Communications, which he took public in 1997. He served as Strategic Planning Advisor at Intelsat, a communications satellite services provider. From 2001 to 2003, he was a Council Member at Harvard’s Kennedy School of Government, Belfer Center of Science and International Affairs. He was named the 1998 Ernst & Young Entrepreneur of the Year. He holds bachelor’s degrees in electrical engineering and mathematics, and a master’s degree in engineering from the University of Maryland.

Dr. Jagadeesh Rao is the company’s Principal Scientist. His career spans two decades in the public sector and product R&D for Johnson & Johnson. He leads IGC’s scientists in the development of pharmaceutical and OTC products. He worked for the federal National Institutes of Health, and for the National Institute on Drug Abuse. His Ph.D. in Neurochemistry is from the National Institute of Mental Health & Neurosciences in India. He did postdoctoral training at the University of Illinois-Chicago.

Claudia Grimaldi is a Director, Vice President, Principal Financial Officer, and Chief Compliance Officer for IGC. She also serves as a Director/Manager Director for some of the company’s subsidiaries. She graduated with highest honors from Javeriana University in Colombia with a bachelor’s degree in psychology. She holds an MBA, graduating with highest honors, from Meredith College in North Carolina. In addition, she has attended the Darden School of Business Financial Management Executives program and the Corporate Governance Program at Columbia Business School. She is currently pursuing her Directorship Certification with the National Association of Corporate Directors. She is fluent in both English and Spanish.

India Globalization Capital Inc. (NYSE American: IGC), closed Wednesday's trading session at $0.39, up 2.0942%, on 68,675 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.14/$.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

President Joseph Biden’s administration hopes that by 2030, therewill be at least 500,000 easily accessible EV chargers on America’shighways; with that in mind, the administration has unveiled aseries of measures to bring about this reality. These measuresinclude agreements with companies that construct and managecharging infrastructure, including Tesla, General Motors, ChargePoint and Ford, among others. All these companies are likely to benefitfrom federal financing if the projects they have in mind forelectric chargers match the revised federal requirements that werepublicly revealed at the same time. In support of this, thePresident Biden hailed Tesla for agreeing to make thousands of itschargers available to EVs produced by other companies. Previously,only owners of Tesla’s vehicles had access to the company’sfast-charging stations across the United States. Tesla has formallycommitted to opening up no less than 7,500 of its charging stations across the United States to be used by electric vehicles that arecompatible before the end of 2024. Of these, 3,500 will be Tesla’s250-kW fast chargers located along major highway routes, along withthe Level 2 chargers the carmaker offers at places such asrestaurants and hotels. As charging stations become more universal,there will soon be no difference between the charging system of amodel from a maker such as Mullen Automotive Inc. (NASDAQ: MULN) and the charging systems of other players in the EV space in thecoming years.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Wednesday's trading session at $0.2556, up 0.353357%, on 146,533,182 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.18/$4.1799.

Recent News

SideChannel Inc. (OTCQB: SDCH)

The QualityStocks Daily Newsletter would like to spotlight SideChannel Inc. (OTCQB: SDCH).

SideChannel (OTCQB: SDCH), a provider of cybersecurity products and services to emerging,middle-market and enterprise companies, was featured in a recent Benzinga article. The piece, titled “EXCLUSIVE: Ex-KGB Cyber Criminals with Ties toMoscow Could Steal Your Cannabis Business Info & Money, ExpertWarns,” includes excerpts from an exclusive interview with SDCHfounder and CEO Brian Haugli. “Forget the evil nerd in a dark basement. That’s Hollywood. Mostlikely, if you’re in the cannabis industry, your hackers are partof global organizations that have turned hacking into a lean, meanmoney-making machine,” the article reads. “Haugli explained thatcannabis companies are facing similar issues that industrialagriculture dealt with several years ago. ‘Agricultural companiesunderstood that their filtration and irrigation systems, machinesand greenhouses are all controlled by a corporate network andconnected to the internet,’ Haugli said, adding that companies likeMonsanto and others began addressing this situation years ago andcannabis must catch up.”

To view the full article, visit https://ibn.fm/gZvX1

SideChannel Inc. (OTCQB: SDCH) simplifies cybersecurity for mid-market companies by matching them with highly experienced information security officers at a cost lower than building an in-house information security team or hiring a full-time CISO.

SideChannel’s team of virtual Chief Information Security Officers (vCISOs) possesses a combined 400-plus years of experience in cybersecurity. They’ve honed their skills and abilities in places like Anthem, Dick’s Sporting Goods, Best Buy, TD Bank and the Pentagon. SideChannel lends this talent to clients, creating value in the form of a bespoke cybersecurity program perfectly sized for the growing enterprise.

SideChannel is committed to creating top-tier cybersecurity programs for SMBs to help them protect their data and assets. To date, SideChannel has created more than 50 multi-layered cybersecurity programs for its clients.

 

Reports show that cyberattacks on SMBs have increased in recent years, as organizations’ network attack surfaces have grown exponentially with remote and in-office workers increasingly relying on cloud environments, mobile devices, software applications and third-party suppliers to conduct business.

SideChannel continues expanding its service offerings, workforce and customer base, attracting over 20 virtual CISOs to serve across industries including fintech, biotech, healthcare, manufacturing, legal, defense and technology services. The company is based in Worcester, Massachusetts.

Market Opportunity

An analysis from ReportLinker states that the global cybersecurity market is expected to grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, recording a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving cyber security market growth, according to the report.

A lack of cybersecurity professionals and the budget constraints among SMBs and start-ups in developing economies are expected to hinder market growth. Cybercriminals are using automated techniques to attack SMBs’ networks to take advantage of their weak security infrastructures. To save money, time and resources, SMBs are seeking cybersecurity solutions.

Enclave

Enclave expands upon SideChannel’s cybersecurity service offerings by solving a pervasive network security problem with a simple tool.

A comprehensive cloud and network security solution, Enclave enables IT teams to contain breaches faster, reduce network outages, minimize latency and strengthen overall security defense.

Enclave creates the foundation for a Zero Trust network security model IT can build upon.

With Enclave, IT can easily segment their company’s network, organize personnel and computing devices at the employee workload level, and implement security controls across all network segments.

Enclave was designed and purpose built to serve the growing security needs of SMBs, a traditionally underserved market that is more prone to cyberattacks but has limited protection due to smaller budgets, inadequate IT security staffing and a lack of cybersecurity awareness among top executives.

Enclave is an affordable and effective network security solution that shrinks the attack surface area exposed to a cyber intruder and significantly reduces the amount of effort required to operate securely.

Management Team

Brian Haugli is CEO of SideChannel. He has led programs for the U.S. Department of Defense, the Pentagon, and Fortune 500 companies. He is an expert on National Institute of Standards and Technology guidance, threat intelligence implementations and strategic organizational initiatives. He is a professor at Boston College, Woods College of Advancing Studies Master’s Program in Cybersecurity. He is also a contributing author for the Wiley book ‘Cybersecurity Risk Management’.

Ryan Polk is CFO at SideChannel. He has been the principal of Perissos Partners, an executive consulting firm, since June 2017. He also served in executive roles in the portfolio companies owned by Lacy Diversified, with combined revenue approaching $2 billion. He served as the Vice President for Corporate Financial Planning and Analysis for Brightpoint, a publicly traded, Fortune 500 mobile device logistics company. He earned a bachelor’s degree in accounting and industrial management from Purdue University.

Nicholas Hnatiw is Chief Technology Officer at SideChannel. Prior to joining the company, he served as the technical director for network operations supporting U.S. Cyber Command, U.S. Intelligence Agencies and other Department of Defense research organizations. He was also the CEO of Loki Labs, a cyber security firm. He earned a bachelor’s degree in computer engineering and computer science at the University of Massachusetts, Amherst.

Bill Roberts is SideChannel’s CISO. He most recently served as the vice president, IS & CISO for Hologic Inc., a global medical device company, where he established cyber security and IT compliance programs. Prior to Hologic, he was vice president of information security for Cytyc Corporation, which was acquired by Hologic in 2007. At Cytyc, he managed global IT as the company grew from 140 employees to 1,500 and from $40 million in revenue to over $750 million.

SideChannel Inc. (OTCQB: SDCH), closed Wednesday's trading session at $0.115, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0675/$0.18.

Recent News

REZYFi, Inc.

The QualityStocks Daily Newsletter would like to spotlight REZYFi, Inc.

Earlier this month, Assemblymember Matt Haney introduced a measure to legalize the sale of nonalcoholicbeverages and food at marijuana lounges and retailers in the stateof California. California was the first state in the country tolegalize the use of medical cannabis in 1996, following theapproval of Proposition 215. Two decadeslater, the state legalized the recreational sale and distributionof the drug following the passage of Proposition 64. Haney stated that while some cafes did permit the consumption ofmarijuana, the no-drinking and no-eating rule made them less thanideal. Under the proposed measure, called Assembly Bill 374, the consumption of alcohol would still be prohibited in cannabiscafes. If approved, the measure and its counterpart introduced inthe California Senate would permit cities and localities to allow the consumption of drinks as well as food at marijuana retailers. Robert Solomon, cochair ofthe UCI Center for the Study of Cannabis, stated that the biggest challenge for individuals who operatelegal marijuana shops in the state was heavy taxes. The state levyon cannabis retail sales currently stands at 15%. Those hefty taxes have deeply eaten into the profit margins ofcannabis companies, and these companies have had to reach out tofunding sources such as REZYFi Inc. in order to keep growing.

REZYFi, Inc. is a cannabis mortgage bank servicing the needs of both traditional and non-traditional consumers and businesses. Its target markets include licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, and companies and individual homeowners seeking a variety of real estate-related first and additional mortgage-based financing and project-specific financings, such as solar installations and real estate development projects.

Headquartered in Miami, Florida, REZYFi operates through two wholly owned subsidiaries – REZYFi Lending, which primarily addresses emerging real estate-related financing opportunities, and ResMac Inc., the company’s traditional mortgage origination, correspondent and servicing operation. REZYFi is currently licensed in 34 U.S. states, with plans to expand to all remaining states later this year.

REZYFi is positioned as one of first cannabis mortgage bankers in the U.S., while most traditional lenders are still reticent to serve the state-licensed cannabis industry.

Operations

REZYFi Lending

REZYFi Lending leverages a wide network to offer options such as 15- and 30-year fixed-rate loans, FHA loans, VA loans, reverse mortgages, jumbo loans and adjustable-rate mortgages.

Looking ahead, the company expects increased funding in marketing and loan agents to drive significant origination growth over the next two years, further supported by the planned launch of a high-margin cannabis division later this year.

ResMac Inc.

ResMac has been in operation for 13 years, having closed more than 20,000 loans for more than 15,000 clients. The company expects to accumulate $285 million in retail origination in 2023, alongside $250 million in wholesale origination for the same period. ResMac is further targeting $600 million in origination through its mortgage correspondent operations for 2023.

Through its ResMac subsidiary, REZYFi operates as a direct lender and originator of residential mortgages, with active mortgage correspondent and mortgage servicing operations. Through its correspondent segment, ResMac primarily purchases and aggregates residential mortgages from trusted third-party originators.

The company intends to harvest the database of customers within its mortgage servicing operations as an essential source of additional growth, especially relative to the new alternative residential loan programs being offered.

Corporate Strengths

  • Experience – REZYFi is led by a seasoned management team with significant expertise spanning a wide range of real estate and financing subsectors. The team also has extensive experience in the cannabis and hemp marketplace, which the company intends to leverage as it navigates the changing landscape of the cannabis industry while sourcing the best opportunities in the sector.
  • Network of Independent Brokers – Over the past five years, REZYFi has developed an extensive network of independent mortgage-related brokers and licensed loan officers. The company is currently training the network members on its new service offerings, with many already launching sales efforts. REZYFi believes this network will be a vital asset moving forward as other firms in the sector terminate relationships in the face of slowing mortgage business in a rising interest rate environment.
  • Proprietary Technology – REZYFi has invested heavily in designing, building and implementing proprietary automated/machine learning technology to shorten loan processing timeframes and increase efficiencies, allowing it to operate its legacy business at staffing levels meaningfully below those of its competitors.

Market Overview

REZYFi’s diversified approach to the real estate lending sector positions it to capitalize on growth in multiple verticals in the years to come.

In the first quarter of 2022, lenders issued 2.71 million residential loans, with the average balance for a first mortgage climbing to a record high of $298,324 in 2021, according to the Mortgage Bankers Association. This trend is expected to continue, with Freddie Mac forecasting a 10.4 percent increase in home prices in 2022 and a 5.0 percent bump in 2023. Growth prospects in the cannabis industry paint a similar picture.

The National Association of Realtors® issued a report in April 2021 examining the correlation between cannabis legalization and real estate demand. In states where prescription and recreational cannabis use is legal, more than a third of surveyed agents reported an increase in demand for warehouses. Likewise, 23 percent of those surveyed reported an increase in demand for storefronts, and 28 percent observed increased demand for land. As other states look to join the 19 that have embraced full cannabis legalization, this rising demand could create an opportunity for REZYFi’s cannabis-focused initiatives.

In total, an analysis by market research firm Business Research Insights projects the global loan servicing market to reach a value of nearly $1.5 billion by 2028, up from $680.8 million in 2021. Those figures represent a CAGR of 11.0 percent during the forecast period of 2022-2028.

Management Team

John Vu, Esq., is CEO of REZYFi, Inc. He has more than two decades of experience in the mortgage and commercial banking industry. He has filled many senior and executive management positions in high-producing mortgage banks, including C-level assignments. He has also served as general counsel for a nationally associated commercial bank. Mr. Vu brings considerable cannabis industry expertise to REZYFi. He has served as a corporate attorney to multiple cannabis cultivators, manufacturers and retailers.

Ji Ji Zhang, Esq., is CFO of REZYFi, Inc. He is a multifaceted entrepreneur who owns a law firm, a portfolio of hotels and a high-producing mortgage bank. Mr. Zhang is also an investor in the development of a cannabis business park. He brings more than five years of experience in mortgage banking to REZYFi, having developed Freddie Mac and HUD licenses and amassed a managed portfolio valued at over $300 million.

Kevin Heckemeyer is President of REZYFi, Inc. He has more than 25 years of experience in mortgage banking. He has built and sold several high producing mortgage businesses. In his current roles with ResMac, he is responsible for production and operations.

Spencer Dang is Chief Credit Officer of REZYFi, Inc. He has more than a decade of experience in mortgage operations. He is a direct endorsement underwriter for HUD and has specialized in non-QM underwriting. Under his watch as an underwriter, he has never had a single repurchase.


Recent News

chart

Coyuchi Inc.

The QualityStocks Daily Newsletter would like to spotlight Coyuchi Inc.

Coyuchi, the gold standard in sustainable luxury home goods, has beendriven by four foundational pillars: protecting the planet,innovating circular design, sustainable living, and communityenrichment. “Coyuchi’s line of products includes luxury organicbedding, sheets, towels, apparel, and other home goods, which areproduced using 100% organic cotton materials. With a seasonedleadership team, a robust e-commerce shopping experience, and ahealthy customer base, Coyuchi is preparing to enter a new phase ofgrowth as the world awakens to sustainability at scale… Coyuchicontinues to push the organic textile market forward through itscircular initiatives and supporting cross-industry sustainability.The company is differentiating itself through an omnichannel andcircular business model, which has proven to be a clear draw forcustomers,” a recent article reads. “In the future, Coyuchi plansto add new markets and products to its customer offering. ‘Ourcustomer is asking Coyuchi to help curate an assortment of naturaland sustainable items for their whole home,’ CEO Marcus Chungexplained. ‘We’re looking at solutions like natural laundrydetergents that will complement products like our wool dryer balls– useful products that help extend the life of their home textilesthat customers have come to count on us.”

To view the full article, visit https://ibn.fm/chABn

Coyuchi is the gold standard in sustainable luxury home goods. The company offers sustainably produced luxury organic bedding, sheets, towels, apparel, and other home goods for the environmentally conscious home. With a timeless, coastal-inspired aesthetic, Coyuchi uses only 100% organic cotton materials to manufacture all of its textiles.

The Company was built upon four foundational pillars: protect the planet, innovate circular design, live sustainably, and enrich the community. These guiding principles have proven an effective market strategy. In 2021, Coyuchi earned $33.3 million in net sales, amounting to 26% YoY growth (the industry average is only 5%). It also experienced 2x customer growth to 200,000 active customers, averaging a 35% customer repeat purchase rate.

With a seasoned leadership team, a robust e-commerce shopping experience, and a healthy customer base that drives the fast-growing organic luxury market, Coyuchi is prepared to propel a new phase of growth as the rest of the world finally awakens to sustainability at scale.

A Lucrative Market Ripe for the Taking

The global market for organic bedding, which was estimated at $814.3 million in 2020, is projected to reach $1.1 billion by 2027, growing at a CAGR of 4.9% over that period, according to Research and Markets. More specifically, the domestic organic bedding market is estimated at $240.1 million in 2020, according to Statista. Overall, the U.S. market for home textiles is currently valued at $25 billion annually, and, with a forecast annual growth rate of 5%, it is expected to reach $30 billion by the end of 2025.

Grand View Research reported in 2020 that shifting consumer preference toward high-end lifestyle products is a key factor driving the growth of the organic bedding market. Seventy-four percent of consumers are willing to pay more for sustainable products – a consumer preference that has steadily increased over the last few decades. Millennials especially favor ethical consumption over price when purchasing goods and services, with 83% of millennials reporting that they want the brands they purchase from to align with their beliefs and values (https://ibn.fm/PANNV). With a majority millennial customer base, Coyuchi is poised to capitalize on this trend.

Industry Defining Sustainability Practices

For 30 years, Coyuchi has explored organic farming and sustainable textiles and guarantees the highest environmental and ethical standards through a number of certifications such as The Global Organic Textile Standard (GOTS), Fair Trade Certified, and MADE SAFE®.

Coyuchi continues to push the organic textile market forward through its circularity initiatives and by supporting cross-industry sustainability advocates. Coyuchi’s mission to bring beauty and comfort to every home without sacrificing the health of our planet has resulted in a number of important sustainability checks and balances.

  • A Circular Business Model: Coyuchi has cultivated a holistic 360-degree approach that contributes to the fight against climate change with its take back and recycling program, 2nd Home™. In 2017, it became the first luxury home brand to implement such an initiative, and, since then, the company has eliminated 68,758 lbs. of toxic chemicals from homes and renewed 6,000 lbs. of textiles.
  • The Coyuchi Climate Council: In early 2022, Coyuchi introduced a cross-disciplinary council with a goal of Net Zero Emissions by 2025 and Net Positive Emissions by 2030. The Coyuchi Climate Council brings together influential minds across fashion, regenerative farming, and sustainability who have the knowledge and experience necessary to achieve climate change.
  • C4: The California Cotton & Climate Coalition: Most recently, Coyuchi announced it is a founding member of C4, which includes innovative, sustainable fashion, apparel, and personal care brands like MATE the Label, Outerknown, Reformation, and Trace. Working together pre-competitively, C4 creates a structure for investing in regionally grown, Climate Beneficial™ cotton and directly supports the livelihoods of the farmers that grew it. Coyuchi is the only home industry brand currently involved in the project.

Omnichannel Business Model

Coyuchi differentiates itself through an omnichannel and circular business model, both of which have proven a clear draw for customers. It was an early adopter of an e-commerce sales and marketing approach (over 80% of its sales are directly through coyuchi.com), creating a distinct advantage over incumbents and start-up newcomers in the luxury space. This has resulted in a high lifetime value customer, luxury retail partners such as Nordstrom, and a flagship store in Marin County.

Coyuchi’s Organic Textile Products

Coyuchi’s product assortment consists of consciously designed bedding, bath, apparel, and lifestyle products spread across about 1,400 SKUs. The company believes that its product assortment, produced from 100% organic cotton with Global Organic Textile Standard (GOTS) certification, provides it with a significant competitive advantage. GOTS is the world’s leading textile processing standard for organic fibers, ensuring the organic status of textiles after harvesting raw materials through environmentally and socially responsible manufacturing all the way to labeling, a major environmental and social benefit over conventional cotton product production.

Coyuchi’s focused product assortment consists of four core categories:

  • Bedding – A full suite of sustainable, organic, and high-quality sheets, duvet covers, blankets, and throws.
  • Bath – A luxurious line of towels, bath rugs, and mats.
  • Apparel – Premium apparel for men and women, including robes, sweaters, pants, and pajamas.
  • Lifestyle – The lifestyle category offers 135 SKUs, from organic napkins to crossbody totes.

Management Team

Eileen Mockus is President and CEO at Coyuchi. She has more than 25 years of experience in retail, having held positions in textile development at Patagonia, Pottery Barn Teen, and The North Face. She earned a bachelor’s degree in textiles and clothing from UC Davis and an MSBA from San Francisco State University.
Sejal Solanki is Chief Marketing Officer at Coyuchi. She previously served as the company’s Vice President of E-Commerce. Before joining Coyuchi, she worked at teen clothing giant Charlotte Russe. She oversees the company’s digital marketing, site experience, brand marketing, and e-commerce strategy.

Marcus Chung is Coyuchi’s COO, overseeing supply chain, sourcing strategy, sustainability, and IT. He previously held positions at notable direct-to-consumer brands Third Love and Stitch Fix, as well as national retailer The Children’s Place. He holds a bachelor’s degree from Wesleyan University and an MBA from UC Berkeley’s Haas School of Business.

Margot Lyons is Director of Sustainability and Sourcing at Coyuchi, where she works with strategic partners to ensure all the company’s product sustainability standards are met. She received a master’s degree in textiles and clothing from UC Davis.

Use of Proceeds

This round of funding will be used to increase Coyuchi’s enterprise value through expanded marketing, product category expansion, continued physical presence, and B2B strategic partnerships with wholesalers, and online marketplaces.

Recent News

chart

Silo Pharma Inc. (OTCQB: SILO)

The QualityStocks Daily Newsletter would like to spotlight Silo Pharma Inc. (OTCQB: SILO).

SILO issued US Patent by USPTO titled “PharmacologicalProphylactics Against Stress-Induced Affective Disorders InFemales”

Claims allowed by patent protect use of SPC-15 for treatingstress-induced affective disorders, including anxiety and PTSD

Other therapeutics in company pipeline include SPU-16 to treatmultiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 totreat Alzheimer’s disease

Therapeutics developed by SILO may qualify for FDA’s streamlined505(b)(2) regulatory drug approval pathway

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused onmerging traditional therapeutics with psychedelic research, wasrecently issued US Patent 11,491,120 by the US Patent and TrademarkOffice (“USPTO”) (https://nnw.fm/HmROW). The patent, titled “Pharmacological Prophylactics AgainstStress-Induced Affective Disorders in Females”, enables SILO toexpand its intellectual property and technology rights for treatingrare stress-related medical conditions.

Silo Pharma Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company, is focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as post-traumatic stress disorder (PTSD), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund research that the company believes will be transformative to the wellbeing of patients and the health care industry.

Silo is committed to developing innovative solutions to address a variety of underserved conditions. Combining Silo’s resources with world-class medical research partners, the company looks to make significant advances in the medical and psychedelic space.

Silo works to identify and partner with leading medical universities, providing the needed financial resources to develop safe therapeutic treatments while moving cutting-edge research through the clinical stage and into commercialization. The company is well-capitalized with access to additional funds as opportunities present themselves.

Silo recently engaged Donohoe Advisory Associates LLC for consulting and advisory services in connection with the potential uplisting of Silo’s common shares to the Nasdaq Stock Market.

Research

Silo has entered into research agreements and partnerships with multiple leading medical universities.

The company is involved in a sponsored study with Maastricht University utilizing repeated low doses of ketamine and psilocybin to examine the effects on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The investigator in the Netherlands is acquiring the substances for the study and will then finalize the documentation to submit to the ethics committee.

Additionally, in June 2021, Silo announced its entry into a scientific research agreement with the University of California San Francisco (UCSF). The agreement will leverage four other clinical trials being planned by the university to determine the effects of psilocybin on inflammation. The study will take place at The Translational Psychedelic Research (TrPR) Program at UCSF.

Silo also recently extended its exclusive option agreement with the University of Maryland, Baltimore (UMB) to explore a novel invention generally known as joint-homing peptides. These peptides are being developed for use in the investigation and treatment of arthritogenic processes and can be used for enhanced targeting of therapeutic agents.

This agreement includes the study of two separate peptides. The first is an option and study for the treatment of arthritis. The second is a patented licensed peptide for the central nervous system, with an initial study for MS autoimmune diseases, in addition to rheumatoid arthritis. Animal studies are underway for both initial indications relating to the UMB agreement, with the potential for studies evaluating additional indications in the future.

Finally, Silo signed an agreement with Columbia University granting it an option to license certain assets currently under development, including an Alzheimer’s disease formulation targeting NDMARs and 5-HT4Rs, as well as a prophylactic treatment for stress-induced disorders and PTSD. Both candidates are currently being tested in mice and have already provided early data.

In addition to its university partnerships, Silo entered a joint venture agreement with Zylo Therapeutics Inc. (“ZTI”) focused on the development of ketamine and psilocybin using ZTI’s Z-Pod™ technology for the transdermal time released delivery of therapeutics. In November 2021, the company announced ZTI’s reception of its first ketamine shipment and initiation of loading ketamine into its Z-Pod technology. In a news release, Eric Weisblum, CEO of Silo, called the development an “important milestone” that will help the company “study the benefits of slow-release transdermal release of Ketamine.”

Market Overview

According to Coherent Market Insights, the fibromyalgia treatment market was valued at $2.78 billion in 2018 and has a projected CAGR of 3.3% over the forecast period 2018 to 2026. Fibromyalgia is a condition that causes pain all over the body, sleep problems, fatigue, and emotional and mental distress.

The global PTSD therapeutics market is expected to reach $10.68 billion by 2026 with a CAGR of 4.5% during the forecast period from 2018 to 2026, according to a report by Credence Research. Growing prevalence of PTSD is the chief factor driving the global treatment market. Increases in events such as wars, combat, and interpersonal violence has been a major contributing factor. Other factors like growing emphasis on rehabilitation initiatives by governments for treating their war veterans has also been facilitating the increase in demand for PTSD therapeutics.

Fortune Business Insights reports the global Parkinson’s disease treatment market is predicted to grow to $8.38 billion by 2026, with a CAGR of 8.1% during the forecast period. Parkinson’s is a neurodegenerative disease of the central nervous system which primarily affects the brain, causing uncontrollable shaking and tremors, difficulties in balance and restricted body movement making it difficult for the person to function or perform a daily routine.

Management Team

Eric Weisblum is CEO and founder of Silo Pharma. He has over 25 years of Wall Street experience, most recently in the biotechnology sector. He has served on the board of Aikido Pharma and was the president of Sableridge Capital. He has a proven track record in licensing therapeutic assets and assisting in their development. He brings to the company nearly 20 years of expertise in structuring and trading financial instruments. He holds a bachelor’s degree from the University of Hartford’s Barney School of Business.

Dr. Kevin Muñoz was appointed to the Silo board of directors in October 2020. He teaches biomedical sciences and medical intervention for the Passaic County Technical Institute. He previously served as Director of Operations at Physical Medicine and Rehabilitation. He began his career with Harlem Health Promotion Center in New York City as a research assistant. He earned a bachelor’s degree from the University of Michigan and a Doctor of Medicine from Xavier University School of Medicine.

Josh Woolley, M.D., Ph.D., is a Scientific Advisor for Silo. He is an associate professor in the Department of Psychiatry and Behavioral Sciences at the University of California, San Francisco. He is also a psychiatrist on staff at the San Francisco Veterans Affairs Medical Center. He is the director and founder of the Bonding and Attunement in Neuropsychiatric Disorders Laboratory. He received both his M.D. and his Ph.D. in Neuroscience from UCSF, where he completed his psychiatry residency training.

Charles Nemeroff, M.D., Ph.D., is a Scientific Advisor for Silo Pharma. He directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. He was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine. He received his M.D. and Ph.D. in neurobiology from the University of North Carolina School of Medicine.

Silo Pharma Inc. (OTCQB: SILO), closed Wednesday's trading session at $2.37, off by 3.2653%, on 54,664 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.25/$12.445.

Recent News

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV)

The QualityStocks Daily Newsletter would like to spotlight BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV).

BiondVax Pharmaceuticals is promoting preclinical results of itslead “biobetter” NanoAb drug candidate for conveniently proactivelypreventing COVID

The company’s CEO recently presented the data at the annual BIO CEO& Investor Conference in New York, as well as updates on thecompany’s pipeline for treating autoimmune diseases such aspsoriasis, asthma, psoriatic arthritis and macular degeneration

Monoclonal antibody-based drug product Evusheld recently lost itsEUA authorization as a COVID preventative after FDA findings thatit insufficiently protects against the current wOmicronsub-variants, eliminating the only preventative option forvaccine-intolerant patients

BiondVax nano-sized antibodies may provide superior responses toCOVID both for current and potential future subvariants of thevirus

Pioneering immunotherapy developer BiondVax Pharmaceuticals (NASDAQ: BVXV) is seeing convincingly positive outcomes for preventing andarresting disease in COVID patients during an ongoing preclinicalin vivo study, even as continually evolving variants of the COVIDvirus are shutting down emergency authorization-approved (“EUA”)avenues of treatment that may no longer be effective.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative products for the prevention and treatment of infectious diseases and other illnesses.

In collaboration with the prestigious Max Planck Institute for Multidisciplinary Sciences (MPG) and the University Medical Center Göttingen (UMG), both in Germany, BiondVax is developing a pipeline of innovative nanosized antibody (NanoAb) therapies addressing diseases underserved by current treatments and with large and growing markets, such as COVID-19, asthma and psoriasis.

NanoAbs, also known as VHH-antibodies or Nanobodies, are alpaca-derived nanosized antibodies that exhibit multiple significant competitive advantages over existing antibody therapies, including stability at high temperatures, superior binding affinity, more effective and convenient routes of administration and efficient production. BiondVax is uniquely positioned to advance nanosized antibody innovation from R&D through commercialization.

The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK and Bristol-Myers Squibb.

Since its founding, BiondVax has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influenza vaccine candidate, and it built, owns and operates a 20,000 sq. ft. state-of-the-art GMP biologics manufacturing facility housing its laboratories, production facilities and offices.

Lead Candidate: Inhaled COVID-19 NanoAb

In December 2021, BiondVax signed definitive agreements with the Max Planck Society – parent organization of the Max Planck Institute for Multidisciplinary Sciences– and the UMG to enter a strategic collaboration for the development and commercialization of innovative COVID-19 NanoAbs.

The company is planning a rapid development path that leverages its expertise and capabilities in biological drug development and manufacturing. BiondVax anticipates preclinical proof-of-concept results for an inhaled COVID-19 NanoAb by the end of 2022, with initial Phase 1/2a human clinical trial results expected in 2023.

The intended inhaled mechanism of delivery of BiondVax’s COVID-19 NanoAb formulation may serve as a significant differentiator when compared to approved monoclonal antibodies, which are injected. Inhaled delivery has shown to be cheaper, more convenient and likely safer for patients and providers.

NanoAb Pipeline: Psoriasis, Asthma and More

The COVID-19 NanoAb development agreement is part of a broader five-year research collaboration agreement signed in March 2022 covering discovery, development and commercialization of NanoAbs for several other disease indications with large market medical needs, including asthma, psoriasis, macular degeneration and psoriatic arthritis.

BiondVax has an exclusive worldwide license for development and commercialization of COVID-19 NanoAbs and exclusive options for similar worldwide licenses for NanoAbs for the above mentioned additional large market disorders currently underserved by approved therapeutic antibodies.

Academic research teams from MPG and UMG have verified strong affinity by the new NanoAbs to their biological target molecules and high thermostability. They have also demonstrated strong neutralization by several NanoAb candidates of their respective target molecules. Neutralization studies of the other NanoAbs are expected to begin later in 2022.

Based on the promising results, BiondVax will focus development efforts beginning with the following NanoAbs:

  • NanoAbs targeting IL-17 as drug candidates for the potential treatment of psoriasis and psoriatic arthritis
  • NanoAbs targeting IL-13 and NanoAbs targeting TSLP as drug candidates for the potential treatment of asthma

These are conditions for which the antibody target is validated by existing treatments and the mechanism of action is well understood. Both represent large medical needs and growing markets. BiondVax anticipates preclinical proof-of-concept for at least one of these NanoAbs in 2023. This is in addition to the aforementioned human clinical Phase 1/2a for the inhaled COVID-19 NanoAb therapy, which is also anticipated in 2023.

Market Opportunity

COVID-19 treatment, target of the company’s lead NanoAb therapy candidate, had an estimated market size of $22 billion in 2021.

Future BiondVax drug candidates will target conditions with large markets growing at attractive CAGRs.

The global asthma treatment market was valued at $18.08 billion in 2019 and is projected to reach $26.01 billion by 2027, exhibiting a CAGR of 4.5% during the forecast period, according to Fortune Business Insights. The research firm predicts that the global psoriasis treatment market will grow from $26.37 billion in 2022 to $47.24 billion by 2029, exhibiting a CAGR of 8.7% over the forecast period.

Management Team

Amir Reichman is BiondVax’s CEO. He previously was Head of Global Vaccines Engineering Core Technologies at GSK Vaccines in Belgium. Prior to that, he held leadership roles at Novartis Vaccines’ Global Vaccines Supply Chain Management organization. He was the first employee of NeuroDerm Ltd., a company focused on transdermal drug delivery, and served as Chief Engineer and Senior Scientist until his departure in 2009. He earned a M.Sc. in Biotechnology Engineering from Ben-Gurion University and an MBA in Finance and Health Care Management from the University of Pennsylvania’s Wharton School.

Tamar Ben-Yedidia, Ph.D., is Chief Science Officer at BiondVax. She has more than 30 years of experience in immunology, with specific expertise in the development of vaccines. She began her career with Biotechnology General Ltd., working on development of a recombinant Hepatitis-B vaccine. She later joined the Weizmann Institute of Science, working on the design of a peptide-based vaccine against several pathogens. She is widely published, with numerous refereed articles and invited reviews in various scientific journals. She received her Ph.D. from the Weizmann Institute.

Elad Mark is COO at BiondVax. He has over 15 years of biotechnology industry experience encompassing diverse project stages including feasibility studies, conceptual and detailed design, commissioning, qualification and process validation. Prior to joining BiondVax, he led Novartis’s $800 million investment in a biologics facility in Singapore. With Biopharmax and Antero, both global pharmaceutical engineering companies, he successfully led projects in Israel, China and Singapore. He holds a BSc. in Engineering from the Afeka Tel Aviv Academic College of Engineering and an MBA from the Open University of Israel.

Uri Ben-Or is CFO at BiondVax. He has served as CFO with public life science companies traded on the TASE, OTC and Nasdaq. Ben-Or provides his services to BiondVax through CFO Direct, a company he founded and for which he serves as CEO. He served as the VP of Finance of Glycominds, a leading biotechnology company, and as CFO of a spin-off from Telrad Networks. He also served as a Corporate Controller at Menorah Capital Markets and as an Auditor at PWC. He holds a B.A. in Business from the College of Administration, an MBA from Bar-Ilan University, and is a CPA.

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), closed Wednesday's trading session at $2.28, off by 1.7241%, on 26,618 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.23/$22.90.

Recent News

FingerMotion Inc. (NASDAQ: FNGR)

The QualityStocks Daily Newsletter would like to spotlight FingerMotion Inc. (NASDAQ: FNGR) .

Creatd (NASDAQ: CRTD), the parent company of retail investor activist group CEOBLOC, hascreated an advisory board and announced the first board member;Martin Shen, CEO of FingerMotion Inc. (NASDAQ: FNGR), will join Creatd founder Jeremy Frommer on the board, which willguide the company’s priorities and be a “voice on the ground” withits members. The company noted that board members undergo acomplete vetting and approval process before joining. The new boardis designed to play an essential role in providing governancerecommendations on oversight, assisting with identifying CEOBLOC'sorganizational vision and working to ensure that investors have aplatform to exercise their voice in a meaningful way. CEOBLOC’smission is to bring greater attention to the plight of the retailinvestor in today's public markets. Frommer and Shen are CEOs ofcompanies with stocks that have or are believed to have experiencedan outsized impact from naked shorting effects. “Over the lastyear, there has been significant confusion and mixed messages froma diversity of CEOs and organizations, each with their own agendaand path to action,” said Creatd CEO and chair Jeremy Frommer inthe press release. “The formation of CEOBLOC creates a transparentunderstanding of the environment we're working in where CEOs,executives, and organizations are officially working within anactivist community and forwarding the cause. . . . I am thankfulto Martin Shen for his dedication to joining forces and forging acommon path toward success. Too many CEOs are leveraging thismoment in time as a standalone opportunity rather than devotingthemselves to collectively enacting systemic change. It isimportant for CEOBLOC to distinguish itself as a true ‘membersorganization’ that will effectuate change not just for a singlestock or shareholder base, but for all. We are committed tocompelling Congress to take action and protect the retail investorcommunity."

To view the full press release, visit https://ibn.fm/WPR5S

FingerMotion Inc. (NASDAQ: FNGR) is an evolving technological company with core competencies in mobile payment and recharge platform solutions in China. FingerMotion is in the process of developing additional value-added technologies to market to users.

Founded in 2016, FingerMotion’s goal is to serve over a billion users in the Chinese market and expand its model to other regional markets. The company has offices in Hong Kong, Shanghai and New York City.

Current Offerings

FingerMotion is analyzing and transforming mobile data to improve the lifestyle of the public through technology and innovation. The company’s current offerings include:

  • Telecommunications Products and Services – FingerMotion’s proprietary universal exchange platform, ‘PigeonHole Integration System (PIS)’, offers seamless integration between telecom operators and online stores. The service platform’s offerings include top up and recharge, data plan, mobile phone, loyalty points redemption and subscription plans. The platform offers reliable and secure transactions, real-time reconciliation, simple integration for partners and efficient settlements.
  • SMS and MMS Services – The integrated platform is registered as FingerMotion’s IP in China and provides a robust back-end control panel for corporate partners to manage their own messaging settings. FingerMotion’s clients range from insurance to financial industries, ecommerce firms, airlines and more. The platform offers competitive pricing for partners and provides quick and efficient review to meet timely marketing initiatives.
  • Big Data Insights – FingerMotion brings Big Data-enabled insurance solutions through its Big Data Insights arm, Sapientus. The company’s strategic partnerships with the largest Chinese telecommunications giants allow access to uncover behavior insights through geolocation and mobile data usage. Its Big Data offerings include risk scoring, precise marketing, simplified underwriting and customized products.
  • Rich Communication Services (RCS) – FingerMotion’s RCS platform will be a proprietary business messaging solution that enables businesses and brands to communicate their services to customers via 5G infrastructure. The company expects its RCS platform to offer a better user experience, more efficiency and cost-effectiveness when compared to other solutions.

Telecommunications and Insurtech Markets

The global telecommunications market was valued at $1.74 trillion in 2019 and is expected to grow at a CAGR of 5% from 2020 to 2027. The steady increase is expected to be driven by the adoption of 5G and the increased popularity of Internet of Things (IoT) applications.

The Chinese telecom market was valued at $254.1 billion in 2017 and is also constantly expanding. The current Chinese telecom market is dominated by three mobile operators – China Mobile, China Unicom and China Telecom, which together are responsible for around 1.6 billion active subscribers (https://ibn.fm/zfwy9).

In addition, the insurtech (insurance technology) market was valued at $2.72 billion globally in 2020 and is expected to grow at a CAGR of 48.8% from 2021 to 2028. The large increase is attributed to the rising use of technology solutions for everyday activities like acquiring insurance coverage (https://ibn.fm/TGo7D).

Through its proprietary platforms and technologies, FingerMotion is uniquely positioned to capitalize on the telecom and insurtech markets’ growth and opportunities.

Management Team

Martin J. Shen is the Chief Executive Officer of FingerMotion Inc. He has over 15 years of experience in senior management roles within entrepreneurial startups and large multinational corporations. He has acquired a wide range of corporate management, financial oversight and operation administration expertise through these roles. In his most recent role, he founded Imperial Distributors (formerly known as AP Martin Pharmaceutical Supplies Ltd.), establishing the company as the preferred choice for distributional support to regional pharmacies throughout Western Canada. Before founding Imperial, Mr. Shen served as the Chief Operating Officer and Chief Financial Officer at Wales and Son Industrial (formerly Weir Minerals), a firm specializing in global delivery and support for mining slurry equipment. He began his career at PricewaterhouseCoopers in Vancouver, with work tours in the tax department in Singapore and the tax audit and advisory group in Hong Kong. Mr. Shen is a U.S. Certified Public Accountant and holds a Bachelor of Science from the University of British Columbia.

Lee Yew Hon is the company’s Chief Financial Officer. From 2006 until November 2020, he was the Chief Financial Officer of Cubinet Interactive Group of Companies, and he also took on the Chief Operating Officer role in 2011. During his tenure, he was instrumental in leading Cubinet and building teams across the Southeast Asia region, setting up financial processes within a short time. Mr. Lee spearheaded the growth of Cubinet to other regions, including Europe, the Middle East and Russia. He received his diploma from Tunku Abdul Rahman College in 1996. He is a Chartered Accountant, a member of the Malaysia Institute of Accountants (MIA) and an Associate Member of the Chartered Institute of Management Accountants, UK (ACMA).

Li Li is the Senior Vice President of FingerMotion. She recently served as Advisor to Shenzhen WuYiKa Technology Co. Ltd., a comprehensive service platform dedicated to online service distribution and payment. The company has become a fast and efficient provider of new media marketing solutions for the mobile internet. She has held high-level management positions with multiple industry names, including Hangzhou JiuYue Information Technology Co. Ltd. and Hangzhou LingXuan Information Technology. Ms. Li started her career in 2004, founding Shanghai ChuangYeZZ Network Technology Co. Ltd. and serving as its Vice President. With the close cooperation of local operators, the company launched SMS, MMS, WAP, mobile JAVA games, Hunan Satellite TV e-magazine and other wireless internet services to meet the rapid development of wireless internet and application requirements. She received her degree from Nanjing Academy of Engineering.

FingerMotion Inc. (FNGR), closed Wednesday's trading session at $2.22, off by 9.7561%, on 129,893 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.62/$9.795.

Recent News

Aditxt Inc. (NASDAQ: ADTX)

The QualityStocks Daily Newsletter would like to spotlight Aditxt Inc. (NASDAQ: ADTX).

Consuming too much salt affects an individual’s cardiovascular system and blood pressure negatively while also impacting the immunesystem adversely. A new study has now found that the consumption oftoo much salt weakens the energy supply of regulatory T cells,preventing them from working properly.Regulatory T cells are cells that helpmaintain homeostasis in the body by suppressing immune responsesthat may cause excessive inflammation. The study was carried out bya global team of researchers coordinated by researchers at the MaxDelbrück Center in Germany, Hasselt University and the VIB Center for Inflammation Research in Belgium. A couple of years ago, teams of researchers led byProfessor Dominik Müller of the Max Delbrück Center for MolecularMedicine and Professor Markus Kleinewietfeld of the VIB Center forInflammation Research discovered that diets with too much saltnegatively impacted the energy balance and metabolism of macrophages and monocytes. The investigators alsodemonstrated that salt triggers malfunctions in the mitochondria,which generates the chemical energy neededto power cells in the body. The rising toll of autoimmuneconditions has led various for-profit companies, including Aditxt Inc. (NASDAQ: ADTX), to focus on finding ways to retrain people’s immune systems sothat the progress of autoimmune diseases can be slowed or evenreversed.

Aditxt Inc. (NASDAQ: ADTX) is a biotech innovation company developing technologies focused on mapping and reprogramming the immune system. Aditxt’s immune mapping technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

As further discussed below, the company’s first commercial product is an immune mapping technology, AditxtScore™, which is designed to provide a personalized profile of the immune system.

The company’s preclinical immune reprogramming technology, Apoptotic DNA Immunotherapy™ (“ADi™”), aims to retrain the immune system to induce tolerance, with the goal of addressing vast unmet needs in transplanted organ rejection, autoimmune diseases, and allergies. The company is developing specific ADi™ products for psoriasis, type 1 diabetes, and skin grafting.

Headquartered in Richmond, Virginia, Aditxt also operates locations in Silicon Valley and New York.

AditxtScore™

AditxtScore™ is a proprietary platform designed to provide a personalized, comprehensive profile of an individual’s immune system. The underlying technology, licensed from Stanford University through an exclusive worldwide agreement, offers a highly sensitive and accurate method of detecting and quantifying cellular responses, allowing greater specificity, quantification, and amplification of both clinical and commercial opportunities.

The company’s first commercial application of the platform, AditxtScore™ for COVID-19, delivers timely reports on vulnerability and immune status relating to SARS-CoV-2 and its known variants, giving consumers and physicians the data needed to make informed health decisions. Potential future applications will offer early detection of an array of conditions, including diabetes, cardio-metabolic maladies and hormonal imbalances.

Aditxt’s AditxtScore™ immune monitoring center in Richmond, Virginia, is operational and designed to support the anticipated increased demand for AditxtScore™ as well as related products and services. The company is currently scaling its capabilities at this location, with a goal of processing up to 10 million immune system tests/reports annually.

ADi™

ADi™ is Aditxt’s immune reprogramming platform addressing disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection. The company is commercializing a nucleic acid-based technology called Apoptotic DNA Immunotherapy™ (ADi™) which utilizes a novel approach that mimics the way our bodies naturally induce tolerance to our own tissues (therapeutically induced immune tolerance). Aditxt believes its ADi™ technology platform can be engineered to address a wide variety of indications.

Aditxt is currently developing ADi™ products for psoriasis, type 1 diabetes and skin grafting.

Currently, immuno-tolerance is achievable through chimerism and cell-based therapy, but there is a clinical need for a more practical and cost-effective approach which:

  • Can be made into a product
  • Does not require additional hospitalization
  • Is simple to produce and ship

Preclinical studies have demonstrated that ADi™ treatment significantly and substantially prolongs graft survival, in addition to successfully “reversing” other established immune-mediated inflammatory processes. ADi™ treatment is not expected to require hospitalization, instead being delivered as an injection in minute amounts into the skin.

IP Portfolio

Both AditxtScore™ and ADi™ are supported by a strong IP portfolio.

AditxtScore™, built upon initial technology invented, licensed from and used at Stanford University, is protected by U.S. patents encompassing methods, systems, and kits for detection and measurement of specific immune responses.

ADi™ technology is protected by seven patent families, including:

  • 8 U.S. patents
  • 4 pending U.S. patent applications
  • 86 foreign patents and 14 pending foreign patent applications spanning the EU, Australia, Canada, Japan, China, India and Hong Kong

These patents are broadly categorized into three groups:

  • Autoimmune diseases and Type 1 Diabetes
  • Organ transplantation and a method of producing plasmid DNA to prevent immune activation
  • Composition of matter for a tolerance delivery system for antigens of interest

Aditxt also possesses and/or in-licenses substantial know-how and trade secrets relating to the development and commercialization of its product candidates, including related manufacturing processes and technologies.

Market Overview

The potential market opportunities presented by immune monitoring and reprogramming are extensive, particularly as Aditxt continues to evaluate additional applications for the platforms.

The company’s initial focus on organ transplantation and related autoimmune response provides some insight into the potential of its approach. According to BCC Research, the global organ and tissue transplantation and alternatives market is on course to reach $120.3 billion by 2024, recording a CAGR of 7.4% from 2019. Industry data suggest that approximately 50% of all transplanted organs are rejected within 10-12 years, further highlighting the critical need for a practical, cost-effective solution to harmful autoimmune responses.

Through its focus on the COVID-19 testing market with AditxtScore™, Aditxt demonstrated the wide-ranging potential of its portfolio. Fortune Business Insights estimated the global COVID-19 diagnostics market at $48.64 billion for 2022. While demand for COVID-19 diagnostics is expected to lessen in the coming years, Aditxt will be uniquely positioned to leverage its existing infrastructure stemming from these operations as the company works to advance broader applications for the AditxtScore™ platform.

Leadership Team

Amro Albanna is the Co-Founder, Chairman, and CEO of Aditxt. He has founded multiple startups to commercialize innovations in various industries, including healthcare, enterprise software, telecommunications, nano technology, consumer health, and biotech. Mr. Albanna has led numerous M&A and going-public transactions as a founder, co-founder, and senior executive.

Shahrokh Shabahang, D.D.S., MS, Ph.D., is the company’s Co-Founder, Chief Innovation Officer, and a member of its board. He brings to the team more than 20 years of experience in developing and commercializing life science technologies focused on product and clinical development in the fields of microbiology and immunology.

Corinne Pankovcin, CPA, MBA, is the President of Aditxt. Prior to joining Aditxt, Ms. Pankovcin served as CFO for several world class organizations, including Business Development Corporation of America, Blackrock Kelso Capital and AIG Capital Partners. In these roles, Ms. Pankovcin was responsible for executing portfolio investments and managing significant M&A transactions.

Thomas Farley is the Chief Financial Officer of Aditxt. From December 2015 to June 2020, Mr. Farley was the Controller and Treasurer of Business Development Corporation of America (“BDCA”), a publicly listed business development company. Prior thereto, from January 2011 to August 2015, Mr. Farley was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Prior to joining BlackRock Capital Investment Corporation, Mr. Farley was a Senior Controller for PineBridge Investments Emerging Markets practice. Mr. Farley was also an Accounting Manager for Bessemer Venture Partners prior to his tenue at PineBridge. Mr. Farley began his career with PricewaterhouseCoopers LLP, from 1996 to 2001. Mr. Farley earned his B.S. in Accounting from Long Island University and is a Certified Public Accountant.

Rowena Albanna is the company’s Chief Operating Officer. Ms. Albanna has over two decades of experience in senior leadership roles for both technology startups and public companies. Ms. Albanna’s experience spans a wide variety of industries, including biotechnology, insect control, nanotechnology, consumer electronics, financials, telecommunications, e-commerce, online marketing, medical, and defense.

Matthew Shatzkes is the Chief Legal Officer and General Counsel of Aditxt. As a former partner at an AM Law 50 law firm, Mr. Shatzkes advised a wide variety of healthcare related entities, including biotech companies, on corporate, regulatory, and strategic business matters. Mr. Shatzkes will oversee all aspects of the legal functions at Aditxt, including, providing advice and counsel on governance, regulatory matters, strategic alliances, mergers and acquisitions, and commercial transactions.


Aditxt Inc. (NASDAQ: ADTX), closed Wednesday's trading session at $1.19, off by 2.459%, on 56,940 volume. The average volume for the last 3 months is 113,243 and the stock's 52-week low/high is $1.00/$28.49.

Recent News

Correlate Infrastructure Partners Inc. (OTCQB: CIPI)

The QualityStocks Daily Newsletter would like to spotlight Correlate Infrastructure Partners Inc. (OTCQB: CIPI).

Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance and fulfillment platform fordistributed energy solutions across North America, is focused onretrofitting existing commercial buildings with renewable energysolutions, thereby reducing their carbon footprint and overallenergy consumption. “Through its industry-leading energy solutionand financing platform for the commercial and industrial sectors,Correlate is helping to reduce site-specific energy use. It does sowhile also deploying clean energy generation and energy efficiencysolutions at scale, ultimately helping mitigate the effects ofclimate change,” a recent article reads. “With a significant amountof a building’s energy spent on heating, cooling and lighting,Correlate is looking to address that with solar energy. Its pushfor locally sited solar and energy storage presents an avenue forreal estate owners to reduce their reliance on the national grid.It also allows them to achieve massive cost savings from an energyconsumption standpoint and improve their net operating income whilemeeting carbon reduction goals. The growing conversation aroundbuilding emissions and the advancing recognition of the importanceof controlling them presents a significant opportunity forCorrelate, and the company is committed to taking advantage of it.”

To view the full article, visit https://ibn.fm/D4giA

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), formerly Triccar Inc., through its two subsidiaries, Correlate and Solar Site Design, offers a complete suite of proprietary clean energy assessment and fulfilment solutions for the commercial real estate industry. The company believes scaling distributed clean energy solutions is critical in mitigating the effects of climate change. CIPI is at the forefront in creating an industry-leading energy solution and financing platform for the commercial and industrial sector. The company sees tremendous market opportunity in reducing site-specific energy consumption and deploying clean energy generation and energy efficiency solutions at scale.

The opportunity exists to remove friction between today’s legacy finance process and the needed clean-energy upgrades developed within the company’s program technologies. For the U.S. to reach its 2050 carbon goals, 200,000 commercial buildings must be retrofitted every year until that date. That represents approximately a 5-10x increase over the 2022 industry process run rate.

CIPI announced completion of its acquisition of 100% of the equity of Correlate Inc. and Loyal Enterprises LLC dba Solar Site Design on December 28, 2021. The company notes these acquisitions occurred at a key inflection point of its growth. CIPI currently enjoys channel and sales partnerships with Fortune 250 companies and a strong, proven industry network.

The company’s transparent, leading-edge model changes value delivery for both facility owners and proven solution providers seeking scale. CIPI believes its rapid growth is due to industry demand for actionable, cashflow positive energy programs and the underlying carbon reduction mandates taking effect globally.

CIPI has filed with the SEC for a name change to Correlate Infrastructure Partners Inc., which will more closely reflect its new platform and growth focus. The company has been aggressively moving to rebrand, with efforts including a revised website, investor presentation materials and an investor relations awareness campaign. The company’s shares will continue to trade on the OTCQB Venture Market under the current ‘CIPI’ ticker symbol until changes are approved.

Subsidiaries

Correlate, founded in 2015, is a portfolio-scale development and finance platform offering commercial and industrial facilities access to clean electrification solutions focused on locally-sited solar, energy storage, EV infrastructure, and intelligent efficiency measures. Its unique data-driven approach is powered by proprietary analytics, concierge subscription services, and a highly scalable national fulfillment network to help building owners profit from fully funded, turnkey decarbonization and facility health programs. The platform is designed for commercial and industrial real estate owners seeking to significantly improve net operating income while meeting carbon reduction goals. The platform provides energy programs for commercial property portfolios and requires no upfront capital. Client organizations reduce their risk and generate more profits by leveraging Correlate’s unique payment programs to put more cash in the bank. Deploying Correlate’s strategic energy programs and energy management systems allows property-owning organizations to complete big energy changes across their portfolios.

Solar Site Design, founded in 2013, is a U.S. Department of Energy Sunshot Catalyst winner that provides customer acquisition and project development tools for the commercial solar industry. Its commercial marketplace platform connects highly qualified project opportunities to leading solar construction companies nationwide. The Solar Site Design platform gives commercial and industrial property owners access to the best price for a commercial solar system. Commercial solar analysts provide property owners a site assessment and working project proposal. Solar Site Design’s team of solar engineers finalize the design while approved financing providers help clients explore financing options for their projects. Then, approved contractors in Solar Site Design’s Marketplace bid on the projects, ensuring commercial and industrial property owners get the best estimates for their projects. Solar Site Design’s marketplace process promotes transparency and fair pricing. Its team of experts has nearly 20 years of experience in the solar industry. Only reputable, experienced, certified (NABCEP), licensed, bonded and insured contractors are accepted into the Solar Site Design Marketplace.

Market Outlook

CIPI is in a rapidly growing market with a unique offering to address a total market of more than 5.9 million commercial buildings in the United States, according to the U.S. Energy Information Administration. Currently, the company’s wholly owned subsidiaries, Correlate and the Solar Site Design, have an opportunity pipeline of over $100 million in commercial projects with more than $20 million in awarded backlog. According to the Rocky Mountain Institute, portfolio energy optimization is a $290 billion market in the United States driving deep financial savings and energy efficiency across the commercial sector.

Commercial buildings consume more than 35% of the generated electricity in the U.S. and are underperforming in energy efficiency at every level. These buildings waste energy, emit too much carbon, and are too costly for owners and occupants, but retrofits are not happening at the rate or scale needed.

In today’s real estate market, portfolio property owners own most commercial buildings. Yet most building efficiency work is focused on single buildings, thereby missing the distinct needs of this owner class which has very different needs than traditional owner-occupiers. The diverse nature of commercial buildings, combined with technology and performance uncertainty, make simple energy optimization initiatives – which could greatly reduce energy use and improve building value – financially unattractive, resulting in slow adoption rates. CIPI’s financial instruments and software breakdown this issue known as the “split incentive”, unlocking the majority of the addressable market.

Management Team

CIPI has in place a nationally recognized management team that has been active in the energy market since 2005.

Todd Michaels is President and CEO of CIPI and founder of Correlate. He formerly served as Vice President for Innovation at SunEdison and Senior Director Distributed Solar at NRG Energy. He founded Correlate in 2015 and has 16 years of experience in the energy industry. He graduated from Indiana University with a B.S. in Computer Information Systems.

Channing Chen is CFO at CIPI and Correlate Inc. and brings over 16 years of experience in the solar industry as a developer, financier, and business unit leader. He has held executive management roles at Solar Power Partners (acquired by NRG Energy), where he was a founding employee, SunEdison, and NRG Energy (NYSE: NRG). Most recently, Mr. Chen was founder and Managing Partner at Breakaway Energy Partners LLC – a distributed energy financing and market-making platform. To date, Mr. Chen and his teams have raised over $1.5 billion in financing across residential, commercial, and utility scale solar and energy storage projects representing over 400 MWs. He holds a B.A. in Environmental Chemistry from the University of California at San Diego and an MBA from the University of Southern California. He is also an advisor and early-stage investor to several startup companies in the renewable energy space.

David Bailey is Chief Revenue Officer of Correlate Inc. With over 15 years of executive sales, supply chain management, and energy efficiency experience, he is responsible for ensuring the success of the National Commercial Sales Unit across multiple regional project teams. Mr. Bailey created and launched the Transformation Services team while at Wesco for its multibillion-dollar Distributed Energy Resource division, formerly Westinghouse. His focus was on IoT-enabled efficiency and plant floor automation-based services. Before that, he spent several years in Global Account Sales Management, with GE Supply as a Program Manager, and is a Commercial Leadership Program graduate. Mr. Bailey received his B.S. in Mechanical Engineering from the University of Kentucky.

Jason Loyet is VP of Commercial Sales of Correlate Inc. He is a cleantech executive with over 20 years of experience leading high growth solar energy and software start-ups. Mr. Loyet is a U.S. Department of Energy SunShot Catalyst award winner for his work building the Solar Site Design technology platform. Before joining the solar energy industry in 2005, he founded and sold two software companies in the streaming media (GlobalStreams) and newspaper publishing (MyCapture) industries. Mr. Loyet currently serves as a Member of the Board of Directors for the Tennessee Solar Energy Industry Association (TenneSEIA).

Deke Welling is Head of Project Development and Fulfillment Services at Correlate Inc. He has over 19 years’ experience in the energy industry with an emphasis on renewables and energy efficiency over the past seven years. Prior to entering the renewables sector, Mr. Welling was the CEO of Welling Resources, an energy development company focused on the exploration of oil and natural gas reserves in the U.S. It was this experience that led him into the renewables sector and leading a charge for more sustainable resources. Additionally, Mr. Welling also served as the CEO of Circle L Solar Inc., a top 100 solar installer in the United States since 2016. Through his leadership, Circle L Solar experienced a growth rate of over 2,250% from 2016 to 2019, resulting in his company being listed on the Inc. 5000 list of the fastest growing private companies in the U.S. (Rank #176) and being named ‘Top Energy Company’ and ‘Entrepreneur of Year for the Energy Industry’ by the American Business Awards® in 2019 and again for ‘Entrepreneur of the Year’ in 2021.

Kevin Warren is Head of Construction and Development Engineering at Correlate Inc. He is a solar veteran with over 12 years of experience in the field. Prior to co-founding CLS, Mr. Warren was the owner of Beacon Consulting and has originated, consulted, designed and/or engineered over 122 MW of PV installations ranging from small commercial to utility scale projects throughout Texas, California, Colorado and North Carolina. He holds a Photovoltaic Technical Sales Professional Certification from the North American Board of Certified Energy Practitioners and certifications from Solar Energy International in PV Installation, PV Technical Sales, PV battery-based design, PV design and engineering, and PV operations and maintenance. Along with PV expertise, Mr. Warren is a LEED Green Building Associate, a certified building analyst from the Building Performance Institute, a Certified Renewable Energy Professional from the Association of Energy Engineers and holds a designation in High-Performance Sustainable Buildings from the BOMI Institute. He studied Electrical Engineering at the University of Texas at Arlington.

Tom Kunhardt is Director of Customer Success at Correlate. He previously held a similar position at Clean.Tech and was Corporate Trainer, Learning & Development, at NRG Energy. He has 15 years of experience in the solar and clean energy industries helping homeowners and businesses find solutions to their energy needs. He holds a bachelor’s degree from the University of Massachusetts.

Correlate Infrastructure Partners Inc. (OTCQB: CIPI), closed Wednesday's trading session at $0.95, off by 5%, on 1,349 volume. The average volume for the last 3 months is 12,983 and the stock's 52-week low/high is $0.52/$1.70.

Recent News

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF)

The QualityStocks Daily Newsletter would like to spotlight Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF).

Ucore Rare Metals Inc. (TSX.V: UCU) (OTCQX: UURAF) is engaged in Rare Earth Element (REE) resource development and in commercializing its critical metals separation technology, RapidSX™, for the mining and metals extraction industry. The company is guided by principles of environmental, social and corporate governance (ESG) with a focus on disrupting China’s current dominance of the U.S. REE supply chain.

Ucore’s vision is to become a leading advanced technology company providing best-in-class metal separation products and services to the mining and mineral extraction industry. It plans to aid in the development, through strategic partnerships, of a North American REE supply chain controlled by the U.S. and its allies.

The company intends to contribute to this initiative through the near-term development of a heavy and light rare-earth processing facility in Louisiana and subsequent development of Strategic Metals Complexes (SMCs) in Alaska and Canada, as well as through the longer-term development of its 100%-owned Heavy Rare Earth Element (HREE) mineral resource property at Bokan Mountain on Prince of Wales Island, Alaska.

Ucore is headquartered in Halifax, Nova Scotia.

Projects & Technology

RapidSX™ Demonstration Plant

The Kingston, Ontario, RapidSX™ Demonstration Plant commissioning process is underway. Once commissioned, the plant is designed to demonstrate the commercial capabilities of the RapidSX technology platform.

The RapidSX demo plant will show:

  • The techno-economic advantages of the RapidSX technology platform
  • The processing of tens of tons of heavy and light mixed rare earth element concentrates in a simulated production environment
  • The platform’s ability to operate for thousands of semi-continuous run-time hours
  • Production of high-purity NdPr, praseodymium, neodymium, terbium and dysprosium rare earth elements for early OEM product qualification trials

The demo plant is located within Ucore’s 5,000-square-foot RapidSX Commercialization and Demonstration Facility and is run by its laboratory partner, Kingston Process Metallurgy Inc. (“KPM”).

RapidSX™ Technology

Innovation Metals Corp., acquired by the company in 2020, developed the RapidSX separation technology platform with early-stage assistance from the United States Department of Defense, later resulting in the production of commercial-grade, separated rare earth elements at pilot scale.

RapidSX combines the time-proven chemistry of conventional solvent extraction (SX) with a new column-based platform that significantly reduces time to completion and plant footprint, as well as potentially lowering capital and operating costs. SX is the international REE industry’s standard commercial separation technology and is currently used by all REE producers worldwide for bulk commercial separation of both heavy and light REEs.

Utilizing similar chemistry to conventional SX, RapidSX is not a “new” technology, but it represents a significant improvement on the well-established, well-understood, proven conventional SX separation technology preferred by REE producers.

Strategic Metals Complex

Ucore, engineering partner Mech-Chem Associates Inc. and KPM are developing the full-scale engineering for the company’s first Strategic Metals Complex (SMC). The SMC is a planned REE separation and rare earth oxide production plant slated to commence construction in Louisiana in 2023. It is scheduled to initially process 2,000 tons of total rare earth oxides by the end of 2024, increasing to 5,000 tons in 2026.

Bokan-Dotson Ridge REE Deposit

Ucore has invested over C$35 million to establish and validate the Bokan-Dotson Ridge resource in preparation for mine design and permitting. Initial drilling is complete, and a Preliminary Economic Assessment has been issued. Next steps for the project include a feasibility study, detailed mine design and permit acquisition. The project can be “near shovel ready” for construction in less than 30 months after receipt of the next stage of development funding.

Market Opportunity

According to a report by Grand View Research, the global rare earth elements market was valued at $2.8 billion in 2018 and is forecast to reach a value of $5.6 billion by 2025, achieving a CAGR of 10.4% during the period. Market growth is driven by increasing demand for these elements in the manufacturing of magnets and catalysts for the automotive industry. Rising demand for electric vehicles to reduce CO2 emissions is expected to propel the use of permanent magnets in the production of EV batteries.

China is the major producer and consumer of REEs. To maintain self-sufficiency and to meet future demand, China has been raising the export tariffs on rare earth elements shipped to various countries, including the U.S., Japan, India, Brazil and the European Union. This led to the current supply-demand gap in these countries, as they rely on imports from China.

China reduced the exports of REEs by 72% in the second half of 2010 to preserve its reserves of these elements and continues to export REEs at reduced levels, thereby affecting industries such as automotive, oil and gas, and electronics, which require an ample amount of rare earth elements.

Management Team

Pat Ryan, P.Eng., is Chairman and CEO of Ucore Rare Metals. He began as a director with the company when he developed a heightened interest in critical metals. Before joining Ucore, he founded and led a multimillion-dollar automotive OEM design and lean manufacturing company. His understanding of complex supply chains across international markets has led to a prime positioning as the global auto industry transitions to vehicle electrification. He holds a Bachelor of Engineering degree from Dalhousie University.

Peter Manuel is Vice President and CFO of Ucore. Prior to joining the company, he practiced as a Chartered Accountant for more than 17 years, providing consulting services to companies in a range of industries, with a focus on the financial services and resource sectors. He spent 10 years in England and Ireland providing assurance, strategic planning, corporate finance and other consulting services to a portfolio of both public and private entities. He holds a Bachelor of Commerce Degree from Dalhousie University.

Michael Schrider, MEng, P.E., is Vice President and COO of Ucore. He is a multidisciplinary engineer who has been involved in manufacturing, engineering and managing complex structural and mechanical systems projects since 1989. He was the Founder, President and Chief Engineer of Schrider & Associates and Alton Bay Design, both engineering services firms. He holds a bachelor’s degree in naval architecture and marine engineering from the University of New Orleans and a master’s degree in mining, geological and geophysical engineering from the University of Arizona.

Mark MacDonald is Vice President of Investor Relations at Ucore. He has over 25 years of experience implementing award winning business development and marketing programs at regional and national levels. As Vice President of Sales, he was responsible for Mediapro Communication’s growth as AT&T Canada’s leading B2B sales partner. He subsequently became Atlantic Regional Vice President of AT&T Canada Corp. He holds a Bachelor of Commerce degree from Dalhousie University.

Ucore Rare Metals Inc. (UURAF), closed Wednesday's trading session at $0.903, up 2.4855%, on 22,333 volume. The average volume for the last 3 months is 2,800 and the stock's 52-week low/high is $0.40/$1.05.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.